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Docosahexaenoic acid (DHA) is a major structural fatty acid in brain and is required 
for fetal growth and development. DHA in maternal plasma increases during pregnancy to 
meet the placental transport demands of the fetus.  Previously, we observed that 16:0/DHA 
phosphatidylcholine (PC) increased dramatically in plasma during pregnancy which was 
associated with increased hepatic expression and activity of phosphatidylethanolamine N-
methyltransferase (PEMT), an enzyme that produces PC. Using hepatic tissue from the same 
rodent model, various pathways involved in lipid synthesis and secretion that could also 
support maternal DHA mobilization were presently examined. Targeted mRNA expression 
and immunoblotting assessments were used. In addition, a quadrupole-time of flight tandem 
mass spectrometry lipidomic method using alternating low-energy full-scan MS scans and 
high-energy collision-induced dissociation MS/MS scans (QTOF-MSE) was used to examine 
changes across various acyl species of lipids at baseline, 15 days and 20 days of pregnancy, 
and 7 days postnatal. There was an increased mRNA expression of both ApoA1 and ApoA2, 
consistent with previous data. However, it appears this was not a result of increased expression 
of lipoprotein assembly enzymes examined. Surprisingly, there was no evidence of an 
upregulation of an acyltransferase, but PLA2G15, a phospholipase, was decreased throughout 
pregnancy in both mRNA and immunoblot analysis.  This could be evidence of reduced 
phospholipid remodeling, considering the previous observation of the upregulation of PEMT.  
Lipidomic analyses revealed widespread changes in numerous acyl species of lipids in plasma 
and liver across all pregnancy time-points although comprehensive acyl species identification 
was not possible due to the nature of MSE data.  Nevertheless, there was evidence of depleted 
hepatic DHA levels at the postnatal time point. We have gained further insight into lipid 
synthesis and mobilization throughout pregnancy, and into novel lipidomic techniques. 
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Additional research is needed to determine the lipid species identify of numerous detected 
compounds in the present analysis.  In addition, the decreased DHA status of several hepatic 
lipid species, indicates that future studies examining the post-partum period and the effect of 
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Chapter 1: Introduction 
 
Docosahexaenoic acid (DHA) is an omega-3 fatty acid known for its integral role in fetal brain 
and neural development [1, 2]. Maternal DHA deficiency has been linked to cardiovascular 
dysfunction [3], decreased retinal electrophysiology [4], and spatial awareness [5] of the offspring. 
Several global populations consume low DHA level in their regular diets [6] with 90% of Canadian 
pregnant women consuming <200 mg/d of DHA [7].  Therefore, understanding maternal DHA 
requirements is a public health concern.  However, maternal plasma DHA levels increase during 
pregnancy by 5-7 folds suggesting a metabolic adaptation to meet fetal demand [8].  The underlining 
mechanism behind this adaptation is not fully understood. Reports of gene expression assessments 
of enzymes involved in fatty acyl specific lipid metabolism and lipidomic profiling to identify 
changes in acyl specific complex lipids of maternal tissues during pregnancy are very limited in the 
literature.  Using these approaches with a pregnant rat model could help unravel pathways involved 
in lipid mobilization and synthesis during pregnancy.  
Previously, using a rodent pregnancy model, we confirmed that maternal plasma DHA increased, 
and then attributed most of the increase to a change in palmitoyl-docosahexaenoyl-
phosphatidylcholine (16:0/DHA-PC) (Chalil et al, 2017, submitted). The increase in 16:0/DHA-PC 
was associated with an increase in the expression and activity of phosphatidylethanolamine N-
methyltransferase (PEMT) as well as an increased expression of FADS2. This coordinates well with 
a previous observation that PC synthesized by PEMT is selectively transferred by the placenta to the 
fetus [9]. There is also evidence that PEMT selectively converts DHA-containing 
phosphatidylethanolamine to PC, but that normally, the DHA content of this new PC is rapidly 
lowered through acyl chain remodeling [10]. In this study, we examine the mRNA expression of 
enzymes involved in lipid synthesis including acyltransferases, phospholipases as well as lipoprotein 
assembly enzymes to further understand the mechanism surround DHA mobilization. Based on the 
mRNA expression results, immunoblotting was then used to determine protein levels of enzymes of 
interest. A comprehensive lipidomic analysis of plasma and liver samples was also performed using 
UHPLC-MS/MS analyses with a QTOF-MS/MS (Waters Synapt G2Si mass spectrometer, Waters 
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Limited, Mississauga, ON) using alternating low/high energy scans. This untargeted approach 
provided MS/MS data for all compounds (better known as MSE) which allowed us to establish a 
profile of the most abundant lipid species, and assess lipid profile changes during pregnancy and 




Chapter 2: Biochemical Foundations 
 
Understanding DHA and its role in fetal development requires an in-depth knowledge of 
phospholipids, their synthesis, and remodeling through the Lands’ cycle. As various metabolic 
pathways are involved in the synthesis and secretion of lipids, knowledge of key structural changes 
in acyl specific lipids can shed light on what enzymes are responsible for these transformations. 
Similarly, the transport of these lipids and fatty acyls to the placenta is largely via lipoproteins, 
therefore lipoprotein assembly should also be examined.  
While pregnancy is associated with increased plasma total lipids, and there is considerable data 
on fatty acid profiles during pregnancy, there is little data on fatty acyl species of complex lipids 
across various maternal tissues. Some data on maternal plasma lipidomic profiles during pregnancy 
has been reported [11], but  non-pregnant baseline values were not determined and a metabolic 
perspective including the role of hepatic lipid synthesis and mobilization was not considered. A 
more comprehensive examination of lipidomic changes is needed to potentially identify mechanisms 
leading to hyperlipidemia in pregnancy and selective transport of acyl-specific lipids through 
lipoproteins.  
2.1 Importance of DHA during pregnancy 
DHA has both structural and functional roles in the brain and retina as the brain matter is 60% 
fat of which 35-40% are polyunsaturated fatty acids (PUFA) [12]. DHA makes up 40-50% of brain 
PUFA and it is distributed in membranes of synapses, the cerebral cortex, mitochondria and 
photoreceptors in the retina [2]. DHA is also important for decreasing phospholipid bilayer viscosity, 
and DHA incorporation leads to more efficient signal transduction [13]. In addition, DHA 
metabolites such as N-docosahexaenoylethanolamide appear to mediate synaptogenesis and 
hippocampal neuronal growth [14]. In rat models, a deficient supply of DHA during pregnancy and 
rearing causes impaired learning and spatial awareness in offspring [5, 15]. Maternal plasma DHA 
levels increase during pregnancy in what appears to be a metabolic adaptation to meet fetal demand 
during the third trimester [16] in order to support the brain growth spurt [17]. This increase in 
maternal DHA is largely in the PC pool, and more specifically 16:0/DHA-PC and is associated with 
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PEMT expression and activity (Chalil et al, 2017 submitted). Evidence also points to selective 
placental uptake of PC synthesized by PEMT [9], which is believed provide PC enriched with DHA 
as compared with PC from the Cytidine Diphosphocholine (CDP-choline pathway) [18]. Once 
synthesized, these PC molecules are then incorporated into VLDL for plasma transport to the 
placenta. This points to the to the importance of understanding phospholipid synthesis as they appear 
to be important carriers of DHA during pregnancy  
 
2.2 De novo phospholipid synthesis  
Phospholipids can be synthesized by different pathways which may have a role in DHA 
mobilization during pregnancy and postpartum [9, 19]. “Phospholipids” (PL) is a broad term 
typically applied to membrane lipids that contain a phosphate moiety in the head group.  
Glycerophospholipids tend to dominate cell membrane composition and are characterized by a 
glycerol backbone with a polar head group in the stereospecific number (sn)-3 position. 
Sphingolipids are another type of PL, but contain a sphingoid base backbone rather than a glycerol 
backbone.  The most abundant subclasses of PL are phosphatidylethanolamines (PE), 
phosphatidylcholines (PC), phosphatidylinositols (PI), phosphatidylserines (PS), and 
sphingomyelins (SM). PC is the dominant PL eukaryotic in membranes followed by PE with the 
other types being considerably lower in the plasma membrane bilayer of eukaryotes. Additionally, 
PC is largely found in the outer membrane layer and PE in the inner membrane layer [20].  This is 
due to a larger head group for PC as the choline group in PC is larger and fills the outer curvature of 
membranes, while the smaller ethanolamine group in PE is required for the inner curvature.  There 
is also a tendency for PE to have a higher PUFA content resulting in outward “splayed” acyl chains, 
while PC tends to have a more compact acyl chain profile associated with higher saturated and 
monounsaturated content. 
PL synthesis is a multi-organelle process spanning the cytosol, endoplasmic reticulum, and the 
inner mitochondrial membrane (IMM) [21]. This synthesis is first initiated with the transfer of an 
acyl group from an acyl-CoA to a glycerol 3 phosphate (G3P) catalyzed by glycerol-3-phosphate 
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acyltransferases (GPAT). GPAT, which encompasses 4 different isomers, are found in both the IMM 
as well as the ER [21]. GPAT 1 and 2, which are the isomers found in the IMM, appear to have high 
specificity for saturated acyl CoAs, while GPAT 3 and 4 are found in the cytosol and do not have 
this specificity. GPATs produce 1-acyl-Glycerol-3-phopshate, or lyso-phosphatidic acid (LPA) that 
are further acylated by 1-acyl-glycerol-3-phosphate acyltransferases (AGPAT), forming 
phosphatidic acid (PA). In the committed step for the synthesis of both PE and PC, PA is converted 
into a diacylglycerol (DAG) by lipid phosphate phosphohydrolases. 
The synthesis of PC can occur through multiple pathways, with the primary being the Kennedy 
pathway in hepatic tissue (Figure 1) [22]. The CDP-choline pathway originates with choline kinase 
that phosphorylates choline to P-choline. The phosphorylated choline is converted to CDP-choline 
by CTP-phosphocholine cytidylyltransferase and then PC is formed by either choline 
phosphotransferase (CPT) or choline/ethanolamine phosphotransferase (CEPT). Hepatic tissue is 
also capable of synthesizing PC through the methylation of PE pathway that accounts for ~30% of 
PC in hepatocytes [18, 23]. This PE methylation pathway, unlike the Kennedy pathway, does not 
require choline obtained through dietary means and relies only on PEMT to convert PE to 
phosphatidylmonomethylethanolamine, phosphatidyldimethylethanolamine, and finally PC [24]. 
PE comprises 20-40% of phospholipids in mammalian bilayers, and is synthesized through two 
main pathways. The main pathway of PE synthesis in hepatic tissues is the CDP-ethanolamine 
pathway [25], which is similar to the CDP-choline pathway (Figure 1). Interestingly, ethanolamine 
phosphotransferase which transfers the ethanolamine head-group to a DAG also preferentially 
selective for substrates (DAG) containing DHA in the sn-2 position [26]. This selectivity highlights 
another enzyme integrated into the mechanism of DHA mobilization in pregnancy. PE can also be 





2.3 Phospholipid acyl chain remodeling  
PL in eukaryotes have distinct fatty acid distributions.  Saturated and monounsaturated fatty 
acids are predominantly esterified in the sn-1 position, while polyunsaturated fatty acids, are 
predominantly esterified in the sn-2 position. PL can undergo remodeling of these fatty acids by a 
series of acylation/de-acylation reactions with the help of acyltransferases and phospholipases that 
make up Lands’ cycle (Figure 2) [28, 29]. After the de-acylation by a phospholipase, an “activated” 
fatty acid that is bound to coenzyme A (CoA) can be acylated back into the PL by an acyltransferase. 
This family of enzymes contain isoforms specific for different types of PL, sn-positions for acyl 
placement and specific to affinities for different fatty acids. The expression of acyltransferase 
isoforms is also largely dependent on the tissue type, and they can be influenced by physiological 
state. For example, lyso-PC acyltransferase 4 (LPCAT4) is highly expressed in the epididymis with 
specificity for 18:1 while lyso-PE acyltransferase 1 (LPEAT1) is highly expressed in the brain with 
specificity for 18:0. GPAT 1-4, AGPAT 1-4, and LPCAT 1-4 are possible acyltransferases that 
regulate DHA remodeling during pregnancy through PA synthesis.  
Similarly, there are isoforms of phospholipases with different specificities. Phospholipase A1 
targets acyl groups in the sn-1 position while phospholipase A2 targets acyl groups in the sn-2 
position. The “activation” of the fatty acids is highly similar, as the Acyl-CoA synthetase can be 
fatty acid specific and dependent on its saturation level. Acsl 3/6 are two isomers that have been 
shown to possess a strong affinity for DHA making them possible targets to explain increased DHA 
incorporation into PL during pregnancy [30, 31]. The phospholipase A2 superfamily, which 
hydrolyzes fatty acids in the sn-2 position of phospholipids, has been categorized into 6 distinct 
types that cumulatively include 16 different groups. Each of these groups differs based on their 
mechanism of action, structure, interaction with membranes, and biological activities. A number of 
these groups (Groups 4a, 5, 6, 10, 15, and 16) have been identified to act on certain PC species 




2.4 Hepatic Lipoprotein Assembly  
Plasma lipoproteins are mainly found in 4 types (VLDL, LDL, IDL, and HDL) that differ based 
on their protein density. These particles are made up of a monolayer of PC, cholesterol, and proteins 
that surround nonpolar lipids such as triacylglycerols (TAG) and cholesteryl esters (CE) [38]. The 
proteins found in these vesicles, referred to as apolipoproteins, assist phospholipids in surrounding 
and transferring lipids, while also serving as enzyme cofactors, and receptor ligands. 
The incorporation of DHA into lipoproteins in postprandial state is well documented. Labelled 
DHA infusion in tracer studies shows over 85% incorporation into TAG of VLDL and LDL within 
30 minutes [39].  This incorporation of DHA into VLDL particles appears to be selective when 
compared to palmitate and EPA [40]. DHA has also been shown to incorporate into the inner core 
of HDL particles [41], however the mechanism surrounding DHA incorporation is not well 
understood. Examining enzymes involved in lipoprotein assembly might provide insight into 
mobilization of hepatic DHA into plasma and placenta thereafter to meet fetal demand. 
The dominant apolipoprotein class is Apolipoprotein B (ApoB) and is associated with 
chylomicrons, VLDL and LDL particles.  There are two ApoB  isoforms based on the origin of 
synthesis in either the small intestine (ApoB 48) or the liver (ApoB 100) [42]. Prior to hepatic VLDL 
release, VLDL assembly is initiated by the synthesis of ApoB in the ER followed by its glycosylation 
[43]. The ER also acts as a site of glycerolipid synthesis which occupies the lipid core of the 
lipoprotein, and is transferred into the precursor VLDL by the microsomal triglyceride transfer 
protein (MTTP) [44-46]. The lipid center also contains CE which potentially links the rate of VLDL 
assembly to cholesterol biosynthesis through HMG-CoA reductase [47].  While HMG-CoA 
reductase is considered the rate-limiting enzyme in cholesterol biosynthesis, it is regulated by the 
presence of mature Sterol Response Element Binding Protein (SREBP), a transcription factor that 
also induces the expression of VLDL production and other lipogenic enzymes [48]. Increased 
expression of MTTP or SREBP could indicate that increased hepatic production and secretion of 
VLDL is occuring.  
HDL differs from VLDL and LDL by the presence of apolipoprotein A (ApoA) and its 
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assembly pathway. ATP-binding cassette transporter, sub-family A1 (ABCA1) is a membrane 
protein responsible for the production of HDL particles [49]. By catalyzing the efflux of both PL 
and free cholesterol to ApoA1, it allows the formation of heterogeneous sized HDL particles. The 




















Chapter 3: Rational, hypotheses, and objectives 
 
3.1 Rationale  
Docosahexaenoic acid (DHA) is required for proper neurodevelopment during pregnancy [17].  
There appears to be various physiological adaptations to ensure adequate delivery of DHA to the 
fetus. While much of this research has focused on adaptations by the placenta itself [53, 54], maternal 
adaptions to supply DHA to the  placenta are less studied.  Understanding these maternal metabolic 
adaptations involved with maternal-fetal transport of DHA are important to establish dietary 
recommendations for DHA for women during pregnancy.  Currently, the Institute of Medicine does 
not have such a recommendation, but rather a recommendation of 1.4g/d of 18:3n-3 for women 
during pregnancy [55]. Health Canada recommends 150g/week of fish during pregnancy as a source 
of EPA and DHA, but do not indicate a specific quantity of DHA to consume [56].  A 
recommendation of 200 mg/d of DHA for pregnant women has been made by an expert panel [57], 
but the possibility of increased biosynthesis of DHA and mobilization of DHA was not considered 
in this evaluation of the literature.    
Previous work from our lab has shown that increased 16:0/DHA phosphatidylcholine is 
associated with increased expression and activity of PEMT and increased expression of FADS2.  
Increased expression of FADS2 could result in a higher biosynthesis of DHA from 18:3n-3 and 
partially explain increased DHA concentrations, but does not explain the very specific increase in 
16:0/DHA PC as the DHA produced from FADS2 would be in the form of an Acyl-CoA.  
Interestingly, PC synthesized from PEMT appears to be selectively transferred to the fetus [9]  In 
addition, PEMT has been shown to have selectivity for DHA containing PE substrates, but the 
resulting PC usually undergoes rapid acyl chain remodeling to lower DHA content and have a fatty 
acyl profile similar to the existing PC pool [10].  Examinations of PL synthesis and remodeling 
enzymes during pregnancy are very limited, but acyl chain specificities in PL metabolism could 




The prior observation of increased 16:0/DHA PC in plasma suggests that DHA transport to the 
fetus from the liver is as part of the PC monolayer of lipoproteins. While hyperlipidemia during 
pregnancy is well documented [58], the exact mechanism is not well defined.  Examining lipoprotein 
assembly enzymes during pregnancy could provide additional insight into the increase in 16:0/DHA 
PC in plasma.  
Lastly, the previous observation of increased 16:0/DHA PC during pregnancy was the result of 
a constrained semi-targeted lipidomic analytical approach.  Only day 15 and day 20 of pregnancy 
were examined (selected based on DHA changes in the fatty acid composition data) and only plasma 
PC and liver PC and PE pools were examined. Plasma lipidomic profiles of pregnant women have 
been reported [11] but without any comparison with before or after pregnancy, so it is difficult to 
determine specific adaptations during pregnancy. Lipidomic assessments of all lipid classes from 
baseline through pregnancy to post-partum in plasma and liver could provide further insights into 
adaptations of maternal lipid metabolism during pregnancy and provide potential enzymes and 
pathways to target for further examination.   
 
3.2 Objectives 
This thesis has two main objectives with both contributing to our understanding of maternal 
adaptations in fatty acid and lipid synthesis and mobilization during pregnancy. Both objectives will 
use tissues collected from chow fed Sprague Dawley rats in a pregnancy protocol that included 
baseline, day 15 of pregnancy, day 20 and 7 days post-partum time points.  
The first objective was to examine the gene expression of various PL synthesis and remodeling 
enzymes and of lipoprotein assembly proteins in liver.  Initially, mRNA expression was to be 
examined, and then based on these findings, targeted determinations of protein concentrations were 
completed with available antibodies.  
The second objective was to complete comprehensive, untargeted lipidomic analyses on both 
plasma and liver samples throughout pregnancy.  To complete this objective, UHPLC-MS/MS 
analyses were completed on a QTOF-MS/MS instrument at the University of Waterloo Mass 
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Spectrometry Facility that uses an alternating low/high energy scans to generate MS and MS/MS 
spectra of compounds.  This “MSE” data was then to be processed using Progenesis software package 
(Nonlinear Dynamics, Newcastle, UK) to: 1) determine the most abundant acyl-specific lipid species 
in these tissues and 2) use principal component analysis to determine individual lipids that change 




1. There will be an increased expression of LPCAT1 in maternal hepatic tissue relative to 
baseline to accommodate the incorporation of DHA into lyso-PC. 
2. There will be an increased expression of Acsl 3, to accommodate the increased DHA 
remodeling through acyltransferases.   
3. There will be a decrease in the expression of PLA2G15 in maternal hepatic tissue relative to 
baseline to reduce the remodeling of PC newly synthesized by PEMT.  
4. There will be an increased expression of MTTP, ABCA1, as well as SREBP at the end of 
pregnancy compared to baseline to support increased VLDL assembly. 
5. Plasma 16:0/DHA-PC at baseline and postpartum will be similar, and lower than levels at 
day 20. 





Chapter 4: Gene and protein expression 
4.1 Introduction 
 The increased presence of plasma DHA during pregnancy has been extensively studied, due 
to its key role in fetal development. More recent data have linked this to an increase in DHA in the 
PC pool.  PC appears to have preferential uptake by the placenta [9]. Previous work from our lab 
show an increase in the PEMT pathway through mRNA, protein, and activity assay assessments, 
throughout pregnancy [19]. This is could be an adaptive mechanism for the increased production of 
DHA enriched PC. An examination of PEMT in primary hepatocytes cultured from non-pregnant 
female rats indicated PEMT selectively converted DHA containing PE to PC but the new PC was 
rapid remodeled  to remove DHA so that the final DHA content of the PEMT synthesized PC 
resembled the preexisting pools of PC in the hepatocytes [10]. In previous work, we observed that 
increased 16:0/DHA PC was associated with increased PEMT expression and activity, suggesting 
some form of adaptation in phospholipid acyl chain remodeling during pregnancy. This post 
synthesis remodeling of PC would limit the ability to export DHA as a component of lipoproteins 
during pregnancy. To determine the enzymes responsible for this remodeling adaptation, liver 
samples from a previous study were analyzed using the RT-qPCR and Western blotting technique.   
 
4.2 Design 
All animal procedures were approved by the University of Waterloo Animal Care 
Committee and are in accordance with the guidelines of the Canadian Council on Animal Care. 
The samples that were analyzed were collected in a previous study (as described in Chalil, 2013 
[19]). 
Briefly, twenty-four female Sprague Dawley rats were purchased at 7 weeks of age.  A 
baseline group of non-pregnant rats (n=6) were sacrificed after 7 days of acclimatization while 
others were mated with 6-month old proven male breeders (Envigo, Mississauga, ON Canada) at 
the Central Animal Facility on campus.  All rats were fed a commercial fixed formula rodent diet 
(8640 Teklad 22/5 Rodent Diet, Envigo) providing 3.0 kcal/g with 17% of energy from fat, 29% 
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energy from protein and 54% energy from carbohydrate throughout the study. Pregnant rats (n=6) 
were sacrificed at day 15 and day 20 of pregnancy, and 7 days postnatal.  All sacrifices were by 
exsanguination following anesthesia, using isoflurane, after an overnight fast. Exsanguinated blood 
was collected in the presence of EDTA and plasma was isolated by centrifugation at 1500g and the 
liver was excised, washed in saline (0.9% v/v), and weighed.  Samples were flash frozen in liquid 
nitrogen and stored at -80°C for various analyses.  
 
4.3 Methods 
4.3.1 Gene Expression  
 mRNA expression was determined by reverse transcriptase qualitative polymerase chain 
reaction (RT-qPCR), a technique used to amplify and detect a specific sequence of RNA. RNA 
extraction was performed using Trizol reagent containing RNAse inhibitor. Separation of RNA from 
other cellular component was done using chloroform. After centrifuging the RNA into a pellet, it 
was washed with ethanol and dissolved in water. RNA purity was measured using a NanoDrop 
spectrophotometer, and samples with high purity (260/280 ratio above 1.80) were used for 
subsequent cDNA synthesis by reverse transcriptase. Following extraction from the samples, the 
sequences were reverse transcribed to cDNA for higher stability on a thermo-cycler. The samples 
cDNA, of similar concentrations, were loaded on a plate alongside the forward and reverse primers 
for the intended gene with the addition of SYBR Green. The primers were designed through the 
Primer-BLAST program on the NCBI website and ordered from Sigma-Aldrich with the full list of 
primers and their sequences listed in Table 1. SYBR Green is a fluorescent dye that binds to double 
stranded DNA allowing detection of the product of qPCR. The samples were incubated at 95°C for 
10 min, followed by 40 cycles of 95°C and 60°C in order to amplify the target sequence. The data 




4.3.2 Protein expression 
Immunodetection was used to determine protein levels of the gene products as described 
previously [60].  Liver tissue was homogenized in a buffer (0.25mol/L sucrose, 0.01mol/L tris-HCl, 
0.01mol/L MgCl2, 2.5mmol/L DTT), containing complete protease and phosphatase inhibitors. 
Using a bicinchoninic acid (BCA) procedure, 40 µg of protein was resolved on a 15% SDS-PAGE 
gel and transferred to a polyvinylidene fluoride (PVDF) membrane. Subsequently, non-specific 
binding sites were blocked using 10% milk in TBS-T for 1 hour at room temperature. The membrane 
was then incubated with primary antibodies for PLA2G15 (Sigma-Aldrich, Saint Louis, Missouri 
using a 1:250 dilution) and β-actin (Sigma-Aldrich, Saint Louis, Missouri, using a 1:500 dilution) 
in a 5% milk TBS-T solution for 1 hour at room temperature. The membrane was further washed 
with TBS-T and incubated again for 1 hour at room temp with horseradish peroxidase-conjugated 
secondary antibody (goat anti-rabbit, Santa Cruz Biotechnology, 1:8000 dilution). Finally, the 
membrane was rewashed and using Enhanced Chemiluminescence Western Blotting Detection 
Reagents, the proteins were visualized on a Chemidoc instrument (BioRad, Mississauga, ON). 
Molecular weights of proteins, equal protein loading, and adequate transfer of protein to membrane 
were also confirmed by ponceau staining. 
 For statistical analyses, a one-way ANOVA test was used to determine differences in mRNA, 
protein, and lipids at the different time points of sample collection. All data is presented as means ± 
standard deviations. Statistical significance was determined at P>0.05 via a Tukey post hoc test after 













































There was no clear increase of GPAT, AGPAT, or LPCAT mRNA expression throughout the four-
time points (Figure 3 and 4). There was a significant decrease (maxed at 57%) in AGPAT2 mRNA 
at day 15 and 20 as compared with baseline (P<0.05), followed by a significant increase (218%) at 
7 days postpartum compared to day 20 (P<0.05) (Figure 3). Acsl 3 increased during pregnancy (day 
15 and 20 compared to baseline) while Acsl 6 decreased (day 20 compared to baseline) (P<0.05). 
(Figure 5). 
4.4.2 Phospholipases 
 There was a significant decrease in PLA2G15 mRNA expression at end of the pregnancy 
(day 20 compared to baseline, 56%) (P<0.05), followed by a significant increase at 7 days 
postpartum compared to day 20 (401%) and baseline (P<0.05), suggesting PLA2 downregulation 
during pregnancy (Figure 6). PLA2 G5 and G16 displayed similar mRNA expression patterns to that 
observed with G15. However, this change was only significant in PLA2 G16 (P<0.05), which had a 
37.5% decrease at the end of pregnancy compared to postpartum followed by an increase to baseline 
levels postpartum (Figure 6).   
 Immunoblotting for PLA2G15 resulted in protein level patterns that were similar to patterns 
observed with the mRNA results.  Protein levels were decreased by 47% at the end of pregnancy 
(day 20) as compared with baseline (P<0.05). Expression increased in the postpartum as compared 
with day 20 by 34%, but remained below the original baseline levels (P<0.05). 
4.4.3 Lipoprotein Assembly 
ApoA1 mRNA increased significantly at day 15 and 20 of pregnancy compared with baseline 
(maxed at 337% increase) followed by a 65% decrease 7 day postpartum compared to day 20 
(P<0.05) where it matched day 15 levels.  ApoA2 mRNA expression had a gradual increase 
throughout pregnancy and into postpartum resulting in significant increase at day 20 and maxing at 
175% higher expression at 7 days postpartum as compared with baseline (Figure 9) (P<0.05). There 
was no clear increase for any lipoprotein assembly proteins across pregnancy (Figure 10). ARFRP1 
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mRNA was significantly decreased only at the end of pregnancy (day 20) as compared with baseline 
(37% decrease) (P<0.05), with a slight but non-significant increase in the postpartum (Figure 10). 
PPARPα mRNA had no changes throughout pregnancy, but there was a significant increase in the 
postpartum (107 %) compared to day 20 (P<0.05) (Figure 10). Finally, MTTP mRNA had a slow 
gradual increase throughout pregnancy which did not reach significance until 7 days postpartum as 
compared with baseline (93% increase) (P<0.05) (Figure 10). All other mRNA proteins examined 






Figure 3: Pregnancy Effect on glycerol-3-phosphate acyltransferases (GPAT) and 1-acyl-glycerol-
3-phosphate acyltransferases (AGPAT) mRNA expression in maternal liver. Values with different 
superscripts are significantly different. Values with no superscripts had no significance between the 
4 groups. Significance is determined by Tukey’s post hoc test (p<0.05) following significant F-value 




Figure 4: Pregnancy Effect on Lyso-phosphatidylcholine acyltransferases (LPCAT) mRNA 
expression in maternal liver. Values with different superscripts are significantly different. Values 
with no superscripts had no significance between the 4 groups. Significance is determined by 





Figure 5: Pregnancy Effect on long-chain Acyl-CoA synthetases (Acsl) mRNA expression in 
maternal liver. Values with different superscripts are significantly different. Values with no 
superscripts had no significance between the 4 groups. Significance is determined by Tukey’s post 





Figure 6: Pregnancy Effect on Phospholipase A2 mRNA expression in maternal liver. Values with 
different superscripts are significantly different. Values with no superscripts had no significance 
between the 4 groups. Significance is determined by Tukey’s post hoc test (p<0.05) following 






Figure 7: Pregnancy effect on PLA2GXV protein expression in maternal liver. Significance is 








Figure 8: Pregnancy Effect on Apolipoprotein mRNA expression in maternal liver.  Values with 
different superscripts are significantly different. Values with no superscripts had no significance 
between the 4 groups. Significance is determined by Tukey’s post hoc test (p<0.05) following 
significant F-value by one-way ANOVA.  
 
Figure 9: Pregnancy Effect on Lipoprotein assembly proteins mRNA expression in maternal liver.  
Values with different superscripts are significantly different. Values with no superscripts had no 
significance between the 4 groups. Significance is determined by Tukey’s post hoc test (p<0.05) 










The mRNA levels of AGPAT 2, Acsl 6, PLA2G15 and PLA2G16 all decreased during 
pregnancy, suggesting decreased remodeling of phospholipids during pregnancy. As each of these 
enzymes participates in a part of the remodeling cycle, the decreased overall expression should allow 
DHA enriched PC levels to remain elevated in the liver for export to the plasma. AGPAT2 specific 
action in converting LPA to PA is possibly downregulated in pregnancy to limit the synthesis of 
saturated phospholipids such as PE. This in turn yields higher relative abundance of unsaturated acyl 
chains in PE for conversion to PC. Similarly, the downregulation of Acsl 6 is thought to limit post 
synthesis remodeling of PC to assist in maintaining high abundance of DHA containing PC.  Due to 
a limitation of available antibodies, we were limited to testing PLA2G15 protein levels.  PLA2G15, 
did decrease throughout pregnancy, providing further support of downregulation of acyl chain 
remodeling during pregnancy. PLA2G16 decreased mRNA levels during pregnancy suggest that 
decreased acyl chain remodeling of PC, lyso-PC and PE, as this enzyme has been shown to possess 
phospholipase A1 and A2 activity, and in vivo acyltransferase activity [61, 62]. Similar to previously 
available data, the increased levels of ApoA1 and A2 mRNA levels during pregnancy indicates 
increased lipoprotein production as a mechanism for pregnancy induced hyperlipidemia [63]. This 
occurs despite decreased levels of both ARFRP1 and PPARP α mRNA levels, and no changes in 
other lipoprotein assembly mRNA that we examined. Changes in activity rate could be another 
possible mechanism causing increased lipoprotein production and hyperlipidemia during pregnancy.  
Interestingly, there is a clear increase in the remodeling enzymes mRNA levels in the 
postpartum period. Theoretically, this would result in decreased levels of DHA-enriched PC, but 
previous data does show plasma DHA remains elevated as compared with baseline levels [19].  
Adaptations to mobilize maternal DHA may remain during the postpartum to provide the offspring 
DHA through maternal breastmilk.  Mammary tissue is capable of synthesizing DHA enriched PC 
through mechanisms similar to the liver.  Further examination of gene expression in mammary tissue 
in the postpartum is necessary to evaluate this mechanism of action and understand DHA offspring 
transport during this period. This will, however, require validation in humans as the postpartum 
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phenomena observed presently may be specific to rodents due to a later brain growth spurt that 




Chapter 5: Lipidomic Analyses 
5.1 Introduction 
 The increase of blood lipids through pregnancy is well documented, where total cholesterol, 
LDL, HDL, and TAG can increase as much as four-fold [58]. Examining the fatty acid composition 
of each complex lipid fraction is possible through the use of thin layer chromatography combined 
with gas chromatography.  However, this approach only provides the fatty acid composition of an 
entire lipid class and individual acyl species cannot be identified. Tandem mass-spectrometry can 
provide this information but it has yet to be applied to the study of pregnancy-induced 
hyperlipidemia. We have identified one report of plasma lipidomic analyses in pregnant women  
[11], but mechanistic insights are not possible as baseline data was not collected and dietary 
assessment was not completed. Using a rat model allows us to control collection time points and 
diet.  In addition, we are able to examine liver tissue, the main site of lipogenesis.  To determine the 
most abundant lipid species in both plasma and liver during pregnancy, samples from the same 
previous study [19] were analyzed using a Waters Quadrupole-Time of Flight (QTOF) mass 
spectrometer to generate MS/MS data across all compounds (MSE). This data was also used in 
comparison with previously acquired data in which only day 15 and 20 time-points were examined. 
5.2 Design 
All animal procedures were approved by the University of Waterloo Animal Care 
Committee and are in accordance with the guidelines of the Canadian Council on Animal Care. 
The samples that were analyzed were collected in a previous study (as described in Chalil, 2013 
[19]).  Briefly, twenty-four female Sprague Dawley rats were purchased at 7 weeks of age.  Rats 
sacrificed at baseline, 15 and 20 days of pregnancy and 7 days postpartum and tissues were 





5.3.1 Non-targeted lipidomic analyses 
Lipids were extracted from 50uL plasma or 50mg frozen pulverized liver tissue using a modified 
Folch procedure [65] with 3mL 2:1:0.5 chloroform:methanol:0.2M NaH2PO4 buffer. Lipid extracts 
were diluted in chloroform by a factor of 10 to prevent signal saturation in the mass spectrometer. 
Samples were spiked with an internal standard mix containing a mixture of different classes of 
deuterated lipids at relevant physiological concentrations (Splash Lipidomix, Avanti Polar Lipids, 
Alabaster, AL).  Lipid extracts were dried under a stream of N2, and then resuspended in 100uL 
65:35:5 isopropanol:acetonitrile:water +0.1% formic acid. A reversed-phase, binary multi-step 
UHPLC protocol was used with a C18 Acquity CSH column with dimensions 150mm x 2.1mm x 
1.7 μm (Waters Limited, Mississauga, ON) for plasma samples, and a C18 Ascentis Express column 
with dimensions 150mm x 2.1mm x 2.0μm (Sigma-Aldrich, St. Louis, MO) for liver samples. The 
mobile phase consisted of A: 60:40 acetonitrile:water +10mM ammonium formate +0.1% formic 
acid with pH = 4.3, and B: 90:10 isopropanol:water +10mM ammonium formate +0.1% formic acid 
with pH = 5.8. The gradient protocol used was as follows: 0 – 1.5 minutes it was 32% B, from 1.5 – 
4 min 45% B, from 4 – 8 min 50% B, from 8 – 18 min 55% B, from 18 – 20 min 60% B, from 20 – 
35 min 70% B, from 35 – 40 min 95% B, from 40 – 45 min 95% B, from 45 – 47 min B was 
decreased to 32%, and allowed to equilibrate until the 48-minute mark. The flow was set to 
260μL/min, column temperature at 45°C, and tray temperature at 4°C. A Waters Synapt G2Si 
Quadrupole-Time of Flight (QTOF) mass spectrometer (Waters Limited, Mississauga, ON) was 
used in positive electrospray ionization mode.  The instrument was set to MSE resolution mode, with 
a scan range of 100-1200 and a spray voltage of +2kV. The Waters MassLynx software (version 4.1, 
Waters Limited, Mississauga, ON) was used for extracting ion chromatograms, integrating peak 
areas, and generating MS/MS spectra.  
Data was imported into Progenesis QI (v2.3, Nonlinear Dynamics, Newcastle, UK) for principal 
component analysis (PCA) to detect differences across groups and for preliminary compound 
identification. Progenesis import settings were set to default filters with [M+H]+ and [M+NH4]+ 
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adducts, and the peak filter set to 2. PCA processing uses the low energy, full-scan MS data, which 
can be used to determine the total number of carbons and double bonds in a molecule but cannot 
distinguish between specific acyl species in a complex lipid. This can be used to generate a lipid’s 
“Brutto” species [66].  MS/MS data is required to identify specific acyl chains within a lipid 
(sometimes called “Medio” species) and when possible, ratios of different MS/MS fragments can 
allow determinations of acyl chain -sn positioning (“Genio” species).  Identifications were acquired 
using the ChemSpider search engine using KEGG, LipidMAPS, MassBank, ChemBank, ChEBI and 
ChEMBL databases with a 5ppm precursor tolerance and use both MS and MS/MS data. EZinfo 
v3.0.3.0 was used to generate s-plots between two time-points using orthogonal projections to latent 
structures discriminant analysis (OPLS-DA) models to identify significantly different compounds 
between two time-points.  
PCA retains most of the relevant information from the original dataset but remaps the data in a 
reduced space defined by principal components to explain the variation[67]. Mathematically, PCA 
defines each point using the equation: 
D = T PT + E 
D is the data matrix, T is the score matrix and PT is the loading matrix and E is the matrix of residual 
error. These values are obtained by means of maximum explained variance and orthogonality. Score 
and loading matrices are produced during the analysis that contain the coordinates of the samples in 
space of principal component as well as the importance of each of the original variables in describing 
the principal components respectively. The PCA graphs in this thesis are representations of scores 
and loadings in the space defined by component 1 and component 2, which is considered the most 







5.4.1 Selective analysis 
 
 Several PC and PE species were examined throughout all the time points (Figure 11 and 
12). During pregnancy, there was a significant increase in PC plasma levels of 32:0, 32:1, 34:2, 36:4, 
38:6 (16:0/DHA), and 40:6 (18:0/DHA) (P>0.05) (Figure 11). PC 32:1, 34:1 and 36:1 both 
increased significantly in the postpartum, while 38:6, and 40:6 both decreased during this time point 
(P>0.05) (Figure 11).  Liver PC had subtle but significant changes where 32:0, 32:1, 36:1, 36:2, and 
38:4 all decreased at the end of pregnancy compared with baseline (P>0.05) (Figure 12). 34:0-PC, 
40:6-PC (18:0/DHA) and more clearly 38:6-PC (16:0/DHA) all increased at the end of pregnancy 
as compared with baseline (P>0.05). 32:0-PC, 32:1-PC. 36:4-PC, 38:6-PC (16:0/DHA), and 40:6-
PC (18:0/DHA) all decreased in the postpartum (P>0.05) (Figure 12). 34:2-PE, 36:2-PE, 36:4-PE, 
38:4-PE, and 40:7-PE all decreased with pregnancy (P>0.05), however only 34:2-PE, 36:2-PE, and 
38:4-PE increased again in the postpartum (P>0.05) (Figure 12).  
 
5.4.2 Highest abundance 
 
 The top 85% most abundant lipids in both plasma and liver in baseline rats were first 
determined to establish a referencing point for other time point analyses. The 85% highest abundant 
lipid species in baseline plasma (Table 2 and Table S1) included 802 compounds. Identifications 
were attempted for the top 50% (90 compounds) of which only 33 were positively identified. The 
lipids identified were predominately phosphatidylcholines, in which 38:4-PC, 36:2-PC, 34:4-PC, 
34:2-PC, 38:6-PC and 40:6-PC made up 11% of total abundance. Other lipids such as lyso-PC, and 
TAG were also present but contributed to less than 1% each to the total abundance.  
 The 85% most abundant lipid species in the liver (Table 3) included 158 compounds with 
57 positive identifications. The lipids were mostly PC and TAG in which 10 compounds making up 
over 43% of total abundance with 38:4-PC (18:0/20:4n-6) making up almost 12% of total abundance 




5.4.3 PCA and S-plots 
 
 The principal component analysis graphs for plasma and liver can be found in Figure 13. 
Plasma PC1 and PC2 had explained variance of 29.7% and 16.8% respectively. Liver PC1 and PC2 
had 44.1% and 17.0% respectively. The clustering of each time point (denoted with different colors) 
is indicative of differences being present.  The s-plots of each time point for both plasma and liver 
can be found in Figure 14 and 15 respectively. These s-plots were used to detect significant changes 
between two time-points. Significant compounds can be detected in the top right and bottom left 
quadrants. Most changes are observed when examining baseline vs. day 20 and 28, as well as day 
20 vs. day 28.  
Plasma differences between baseline and day 15 (Table 4) show several TAG and DAG 
species increasing with 20:5 - cholesteryl ester (CE) decreasing. At day 20 of pregnancy, 
hyperlipidemia is quite clear when compared to baseline (Table 5), as we see 60:9 TAG increase 66 
and 32 fold for the two isomers detected. PE and PC species also increased.  Most notable was 38:6-
PE with a 55-fold increase and 38:4-PC with a 32-fold increase. The increase in 38:6-PE (most likely 
16:0/DHA-PE, but not confirmed) is however minimal when compared with 16:0/DHA-PC as the 
PC species had a maximal abundance 59 times higher than that of the PE species.  
When compared with baseline, day 28 plasma samples have changes in several unidentified 
compounds and/or specialized lipids (Table 6). A number of PC and TAG species were elevated at 
day 28 upwards of 8-fold, while 20:5-CE decreased compared with baseline. Fold changes in the 
plasma lipidome at day 15 vs. day 20 of pregnancy (Table 7), day 15 of pregnancy vs. 7 days 
postpartum (Table 8) and day 20 of pregnancy vs. 7 days postpartum (Table 9) reiterates that 
hyperlipidemia occurs during pregnancy with increases in both PE and PC, TAG species and many 
unidentified lipids during pregnancy time points.   
Liver differences identified between baseline and day 15 of pregnancy (Table 10) show 
different TAG species increasing at day 15 of pregnancy, most notable of which was TAG 57:2 with 
a 3.94-fold increase. Comparison between baseline and day 20 of pregnancy (Table 11) shows PC, 
lyso-PC, PE and TAG differences in which only two species (16:0/DHA-PC and 40:5-PE) increased 
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with pregnancy. There was also an increase in 16:0/DHA-PC at day 20 of pregnancy. The 
comparison of baseline to day 28 of pregnancy (Table 12) provides a pattern shared among all 
significant lipid species, which is a decrease in the post-partum. Interestingly many of the changes 
are were unidentified. Differences between hepatic day 15 and 20 of pregnancy, highlighted in Table 
13, show 40:5-PE, 16:0/DHA-PC, 48:5-PC, 50:2 TAG, and 40:8-PC increasing in day 20. In the 
post-partum, 40:5-PC and 40:5-PE continued to increase (Table 14), as highlighted in liver 
differences between day 15 and 28 of pregnancy. There was also a notable decline in 60:12 TAG 
which decreased 3.6 folds in the postpartum.  Finally, Table 15 presents a 5.37-fold decrease in 
16:0/DHA-PC in the postpartum compared to the end of pregnancy (day 20). Similarly, there was a 
decrease in 58:8 TAG, 56:5-TAG, 56:6 TAG, 40:5-PC, 56:8 TAG, 56:7 TAG, and 48:5-PC. 






Figure 11: Changes in plasma phosphatidylcholine species across the four different time points of 
pregnancy.  Bars with different superscripts significantly different across time within a specific lipid. 
Significance was determined by Tukey’s post hoc test (p<0.05) following a significant F-value by 







Figure 12. Changes in liver phosphatidylcholine (A.) and phosphatidylethanolamine (B.) species 
across the four different time points of pregnancy.  Bars with different superscripts were significantly 
different across time within a specific lipid. Significance was determined by Tukey’s post hoc test 
(p<0.05) following a significant F-value by one-way ANOVA. Acronyms: O-, indicates alkyl ether; 
P-, indicates alkenyl ether; DHA, docosahexaenoic acid; 
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810.6095 16.96 38:4-PC 828030 2.34 
786.6087 17.60 36:2-PC 781729 4.54 
754.6257 14.93 34:4-PC 718112 6.57 
758.5778 14.10 34:2-PC 645050 8.39 
806.5777 12.71 38:6-PC 
(16:0/DHA) 
584241 10.03 
834.6079 15.89 40:6-PC 567368 11.64 
829.8066 29.99  517183 13.09 
782.5772 13.54 36:4-PC 497760 14.50 
524.3818 4.60  464964 15.81 
1128.3188 26.97  435349 17.04 
738.6544 13.51  431913 18.26 
496.3490 3.54 16:0 lyso-PC 419808 19.44 
1054.2992 26.14  413553 20.61 
758.2235 21.47  396971 21.73 
980.2799 25.20  363177 22.75 
872.7762 29.30 52:4 TAG 336545 23.70 
832.2421 22.97  336041 24.65 
1047.7415 4.59  334686 25.59 
906.2606 24.16  324301 26.51 
874.7924 30.15 52:3 TAG 312940 27.39 
760.5919 16.82 34:1-PC 301731 28.24 
570.5543 12.76 Cer(d18:0/h17:0) 300530 29.09 
529.4077 3.63  292673 29.92 
803.5468 5.81  261050 30.65 
520.3467 3.06 18:0 lyso-PC 237100 31.32 
815.7056 24.08  232918 31.98 
991.6787 3.52  228315 32.62 
369.3593 29.85  228102 33.27 
896.7762 28.96  215794 33.87 
808.5893 13.61 38:5-PC 212312 34.47 
544.3472 2.97 20:4 lyso-PC 209786 35.07 
369.3590 31.50  207697 35.65 
690.6230 29.84  197924 36.21 
944.7732 27.69  195308 36.76 
788.6222 20.54 36:1 PC 194532 37.31 
813.6906 22.37  182190 37.82 
703.5795 13.23 PE-Cer(37:1) 176004 38.32 
675.6836 31.42  168504 38.80 
522.3612 3.65 18:1 lyso-PC 163804 39.26 
784.5888 14.30 36:3-PC 162719 39.72 
894.7570 28.18  161027 40.17 














369.3573 30.44  156912 41.07 
900.8057 30.15  147340 41.48 
920.7722 28.05  146924 41.90 
898.7899 29.28  145773 42.31 
876.8086 30.94  138728 42.70 
550.6296 19.94  137975 43.09 
637.3108 3.75  136839 43.48 
836.6190 16.99 40:5-PC 132473 43.85 
787.6727 22.49 GlcCer (d16:1/23:0) 130314 44.22 
922.7910 28.93  128447 44.58 
1024.7361 3.52  127475 44.94 
942.7557 26.87  123972 45.29 
570.5542 29.99 Cer(d18:0/h17:0) 123390 45.64 
666.6227 30.44  120747 45.98 
898.7920 29.81  120223 46.32 
627.5399 13.82  119948 46.65 
415.2171 1.86  119798 46.99 
565.5735 21.62  119707 47.33 
946.7896 28.61  113904 47.65 
924.8056 29.78  113483 47.97 
811.6707 20.71 SM (d18:2/24:1) 112056 48.29 
801.6880 23.31  109025 48.60 
1069.7190 4.61  104885 48.89 
593.6046 23.41  104280 49.19 
537.5396 18.39  103861 49.48 
695.5780 29.87  102605 49.77 
887.5669 13.82 38:4-PI 101119 50.05 
762.6038 20.27 34:0-PC 98349 50.33 
877.7267 29.28  97785 50.61 
949.7263 27.69  96946 50.88 
812.6182 18.53 38:3-PC 95966 51.15 
782.5720 12.00  95692 51.42 
920.7750 28.52 56:8 TAG 95003 51.69 
834.7549 29.94 49:2 TAG 90631 51.94 
965.6997 27.69  89043 52.20 
893.7006 29.31  86799 52.44 
848.7727 30.15 TAG 50:2 86448 52.68 
813.6864 22.70 GlcCer (d18:2/23:0) 85172 52.92 
742.5625 12.77  81047 53.15 
917.7005 28.96  80122 53.38 
901.7272 28.95  79809 53.60 





























872.77043 52:4 TAG 30.35 3984831 17.69 
874.78835 52:3 TAG 31.25 3839177 23.24 
782.56953 36:4-PC (16:0/20:4n-
6) 
14.06 2993945 27.57 
758.56969 34:2-PC 15.07 2168399 30.70 
786.59981 36:2-PC 19.75 1958702 33.54 
898.78392 54:5 TAG 30.32 1874840 36.25 
876.80407 52:2 TAG 32.11 1717149 38.73 
806.56947 38:6-PC (16:0/DHA) 13.25 1658626 41.13 
900.80226 54:4 TAG 31.20 1339587 43.07 
829.79925  31.15 1060320 44.60 
768.55460 38:4 PE 18.26 855622 45.84 
893.69962  30.37 819973 47.02 
764.52327 38:6-PE 13.24 807597 48.19 
760.58461 34:1-PC 18.27 777677 49.31 
429.24085  5.37 765697 50.42 
803.54403  5.30 747469 51.50 
895.71552  31.28 696578 52.51 
902.81733 54:3 TAG 32.05 679478 53.49 
808.58369 38:5-PC 14.40 639774 54.42 
848.77080  31.32 600044 55.29 
920.76709 56:8 TAG 29.53 555325 56.09 
832.58177 40:7-PC 18.21 436315 56.72 
922.78313 56:7 TAG 30.48 427786 57.34 
924.80027 56:6 TAG 30.87 426205 57.95 
529.40022  3.03 421322 58.56 
897.73100  32.11 406721 59.15 
803.54379  5.83 406542 59.74 
792.55556 40:6-PC 17.02 390699 60.30 
848.55850  18.25 389976 60.87 
922.78549 56:7 TAG 29.96 381901 61.42 
917.70012  30.00 366185 61.95 
850.78653 50:1 TAG 32.18 350251 62.46 
920.76821 56:8 TAG 28.99 320400 62.92 
944.86227 57:3 TAG 31.26 312142 63.37 
941.69967  28.99 290513 63.79 
917.69868  29.37 282722 64.20 
956.86151  30.38 274599 64.60 
848.76986 50:2 TAG 31.15 274569 64.99 
904.59095  12.68 267470 65.38 
734.56824 32:0-PC 18.25 261905 65.76 
788.61832 36:1-PC 22.09 261309 66.14 














738.64658  13.40 256428 66.88 
815.69480  26.10 252772 67.25 
941.69937  29.54 250203 67.61 
958.87848 58:3 TAG 31.26 248232 67.97 
919.71424  30.29 244829 68.32 
946.77996  29.50 241329 68.67 
904.83251 54:2 TAG 33.00 227035 69.00 
369.35269  32.93 226929 69.33 
894.71950  28.49 217631 69.64 
569.43321  22.07 201880 69.93 
834.75392  31.15 201558 70.22 
536.61320  20.61 194946 70.51 
627.53518  12.68 191443 70.78 
945.72983  30.86 182139 71.05 
943.71461  29.95 176429 71.30 
919.71527  30.92 175368 71.56 
878.81710 52:1 TAG 33.07 166980 71.80 
740.52345  14.19 157480 72.03 
601.51945  31.25 156482 72.25 
775.59333 34:2-PC 15.89 153387 72.47 
904.59068  13.13 152651 72.69 
391.28472  5.37 151807 72.91 
965.69736  28.61 150254 73.13 
531.40855  10.91 144512 73.34 
804.54889  14.16 144434 73.55 
918.75089 56:9 TAG 28.12 144201 73.76 
926.81209  31.91 139863 73.96 
812.65533  26.38 138741 74.16 
577.51691  31.25 138017 74.36 
744.55339 36:2 PE 19.14 134981 74.55 
647.45947  24.16 131426 74.74 
796.57965  16.07 129126 74.93 
946.87843 57:2 TAG 32.10 128133 75.12 
960.89387 58:2 TAG 32.10 127961 75.30 
927.74073  29.95 127427 75.49 
575.50331  30.36 126388 75.67 
915.68562  29.17 126371 75.85 
820.52517  14.06 125109 76.03 
819.51692 40:8-PG 5.21 120621 76.21 
923.74588  32.22 119736 76.38 
888.79936  31.75 118282 76.55 
921.73024  31.45 118273 76.72 
915.68461  28.49 117066 76.89 













756.55368  13.25 115692 77.23 
948.79304  30.71 115116 77.39 
832.58344 40:7-PC 13.27 110603 77.55 
868.73336  28.82 108377 77.71 
813.68365 42:2-SM 23.76 106781 77.86 
907.76361  32.03 105764 78.02 
869.69988  31.33 104268 78.17 
925.72653  29.54 103157 78.32 
575.50403  31.26 101786 78.46 
577.51948  32.11 99890 78.61 
889.66968  28.83 99397 78.75 
929.75722  30.86 98625 78.89 
867.68365  30.23 97340 79.04 
943.71478  30.49 96250 79.17 
716.52398 34:2-PE 14.88 96096 79.31 
780.55146  14.88 93636 79.45 
833.58454  26.38 93542 79.58 
796.52968  14.91 93293 79.72 
960.76902  20.47 89539 79.85 
801.67798  25.09 89163 79.98 
822.75414 48:1 TAG 31.20 88909 80.11 
844.73775 50:4 TAG 29.25 88661 80.23 
970.87694 59:4 TAG 31.20 88176 80.36 
750.55772  17.63 87314 80.49 
967.71472  29.59 87074 80.61 
524.37203 18:0 lyso-PC 4.09 86187 80.74 
982.87570 60:6 TAG 30.30 85991 80.86 
907.77369 56:6 TAG 32.22 85892 80.99 
603.53502  32.10 81053 81.10 
856.58189  17.00 80945 81.22 
862.78410 52:1 TAG 31.64 79632 81.34 
939.68510  28.12 78897 81.45 
968.86058 59:5 TAG 30.31 78615 81.56 
913.89068  31.15 77328 81.68 
927.74499  30.49 75987 81.79 
391.28462  5.83 75591 81.90 
780.55521 36:5-PC 12.06 75304 82.00 
627.53444  18.27 75274 82.11 
828.55188  13.15 74020 82.22 
836.61552 40:5-PC 20.26 73972 82.33 
980.82602  29.37 73510 82.43 
623.50359  13.24 73213 82.54 
984.89254 60:4 TAG 31.20 72757 82.64 














829.68820  30.70 70094 82.85 
980.85947 60:6 TAG 30.00 69370 82.95 
1004.79464  19.92 69187 83.05 
766.55301  15.69 68351 83.15 
948.79995 58:8 TAG 30.42 66419 83.24 
966.84450 59:6 TAG 30.00 66379 83.34 
569.36451  10.91 66169 83.44 
853.72631  31.34 66068 83.53 
817.61093  26.38 65706 83.63 
570.54783  31.15 61492 83.71 
570.54742  11.75 61012 83.80 
766.53749  14.33 60888 83.89 
553.39010  10.92 60208 83.98 
926.81592 56:5 TAG 31.62 59944 84.06 
972.89319 59:3 TAG 32.04 59305 84.15 
819.51693 40:8-PG 5.88 57673 84.23 
824.76978 48:0 TAG 32.25 57494 84.32 
969.73044  30.71 57468 84.40 
923.74567  32.02 57159 84.48 
837.61464  18.25 56472 84.56 
820.73836 48:2 TAG 30.27 56397 84.65 
680.63316  32.92 55024 84.73 
947.74555  31.91 54662 84.80 
875.19253  31.25 53732 84.88 
948.79651  29.92 53073 84.96 
475.41446  22.04 52773 85.04 
 
1Compound detection was performed in Progenesis QI (v2.3) using M+H and M+NH4 adducts and 
default import filtering strength. Peak filtering was set to 2, and identifications were acquired using 
chemspider search engine using KEGG, LipidMAPS, MassBank, ChemBank, ChEBI and ChEMBL 
databases with 5ppm precursor tolerance. Identifications were verified with lipidmaps for incorrect 













Figure 13. Principal Component Analysis graph for A) Plasma and B) Liver. The distinguishable 
clustering of each group is indicative of differences being present. The gray cloud is an overlay of the 
different compounds detected across the samples. Compounds that are closer to a particular cluster is 
















Figure 14.  S-plots of plasma samples derived from OPLS-DA. A) Baseline vs. Day 15 B) Baseline 
vs. Day 20 C) Baseline vs. Day 28. Variables in the upper right part and in the lower left part are up-





























S-Plot (Baseline = -1, Day 15 = 1)





























S-Plot (Baseline = -1, Day 20 = 1)





























S-Plot (Baseline = -1, Day 28 = 1)










Figure 15.  S-plots of plasma samples derived from OPLS-DA. A) Day 15 vs. Day 20 B) Day 15 vs. 
Day 28 C) Day 20 vs. Day 28. Variables in the upper right part and in the lower left part are up-





























S-Plot (Day 15 = -1, Day 20 = 1)





























S-Plot (Day 15 = -1, Day 28 = 1)





























S-Plot (Day 20 = -1, Day 28 = 1)









Figure 16.  S-plots of liver samples derived from OPLS-DA. A) Baseline vs. Day 15 B) Baseline vs. 
Day 20 C) Baseline vs. Day 28. Variables in the upper right part and in the lower left part are up-






























S-Plot (Chow Baseline = -1, Chow Day 15 = 1)





























S-Plot (Chow Baseline = -1, Chow Day 20 = 1)





























S-Plot (Chow Baseline = -1, Chow Day 28 = 1)










Figure 17.  S-plots of liver samples derived from OPLS-DA. A) Day 15 vs. Day 20 B) Day 15 vs. Day 































S-Plot (Chow Day 15 = -1, Chow Day 20 = 1)





























S-Plot (Chow Day 15 = -1, Chow Day 28 = 1)





























S-Plot (Chow Day 20 = -1, Chow Day 28 = 1)




Table 4. List of compounds significant in plasma according to s-plot between baseline and day 15. 
Compounds are ordered based on their fold change. 
M/z Identification q Value Max Fold Change Highest Mean 
288.2902  5.23E-04 213.99 Baseline 
954.8468 58:5 TAG 0.07 7.71 Day 15 
681.4864  0.068 7.40 Day 15 
950.8147 58:7 TAG 0.07 6.20 Day 15 
994.8787 61:6 TAG 0.067 5.68 Day 15 
665.5123  0.077 5.60 Day 15 
660.5574 38:5 DAG 0.077 5.32 Day 15 
1101.8442  0.207 5.04 Baseline 
601.5195  0.079 4.90 Day 15 
926.8184 56:5 TAG 0.057 4.63 Day 15 
948.8004 58:8 TAG 0.078 4.58 Day 15 
671.5760  0.148 4.54 Baseline 
972.8024 60:10 TAG 0.078 4.42 Day 15 
957.7875  0.068 4.26 Day 15 
996.8029 62:12 TAG 0.094 4.15 Day 15 
907.7687  0.069 4.03 Day 15 
973.7611  0.067 3.98 Day 15 
711.5687  0.125 3.93 Baseline 
 972.8020 60:10 TAG 0.089 3.91 Day 15 
931.7725  0.045 3.87 Day 15 
947.7447  0.037 3.75 Day 15 
924.8056 56:6 TAG 0.082 3.67 Day 15 
711.5686  0.115 3.57 Baseline 
570.4589  0.002 3.49 Day 15 
658.5401 ** 0.113 3.39 Day 15 
929.7581  0.056 3.39 Day 15 
1074.7388  0.014 3.09 Baseline 
466.4100  1.26E-04 3.06 Day 15 
945.7309  0.041 3.05 Day 15 
989.6998  0.032 3.04 Day 15 
953.7583  0.082 3.02 Day 15 
614.4847  0.01 2.99 Day 15 
682.5413  0.095 2.99 Day 15 
969.7305  0.077 2.96 Day 15 
969.7284  0.059 2.93 Day 15 
554.4629  2.94E-04 2.89 Day 15 
968.8624 59:5 TAG 0.079 2.88 Day 15 
973.7295  0.05 2.87 Day 15 
658.5107  0.008 2.86 Day 15 
839.6982  0.006 2.84 Baseline 
727.5438  0.113 2.82 Baseline 
598.4892  2.94E-04 2.82 Day 15 
953.7582  0.065 2.82 Day 15 
841.7154  0.005 2.71 Baseline 
526.4327  0.008 2.70 Day 15 
642.5127  0.003 2.60 Day 15 
923.7461  0.067 2.59 Day 15 
550.3881 20:1 lyso-PC 0.024 2.48 Baseline 
907.7726  0.076 2.45 Day 15 
47 
 
M/z Identification q Value Max Fold Change Highest Mean 
709.5894  0.100 2.44 Baseline 
730.5645  0.015 2.43 Day 15 
725.5633  0.122 2.41 Baseline 
672.5258  0.095 2.38 Day 15 
905.7574  0.08 2.37 Day 15 
628.5003  0.082 2.36 Day 15 
921.7307  0.071 2.35 Day 15 
702.5363 34:1 PnE 0.02 2.29 Day 15 
1063.665  0.037 2.27 Baseline 
552.4035 20:0 Lyso-PC 0.041 2.21 Baseline 
927.7437  0.078 2.21 Day 15 
480.3462 O-16:1 or P-16:0 
Lyso-PC 
0.056 2.18 Baseline 
943.7158  0.059 2.17 Day 15 
538.4233 O-20 Lyso-PC 0.067 2.16 Baseline 
584.473  0.089 2.14 Day 15 
808.5858 38:5-PC 0.096 2.11 Day 15 
482.4051  0.015 2.10 Day 15 
510.3943 O-18:0 Lyso-PC 0.068 2.07 Baseline 






Table 5. List of compounds significant in plasma according to s-plot between baseline and day 20. 
Compounds are ordered based on their fold change. 
M/z Identification q Value Max Fold Change Highest Mean 
1061.6507  0.019 88.48 Baseline 
974.8169 60:9 TAG 3.46E-04 65.91 Day 20 
1063.665  0.004 58.55 Baseline 
764.5226 38:6-PE 2.51E-05 55.51 Day 20 
1039.673  0.002 40.66 Baseline 
1087.6637  0.004 37.26 Baseline 
974.8172 60:9 TAG 2.00E-04 32.43 Day 20 
924.8681  3.56E-04 32.08 Day 20 
954.8468 58:5 TAG 1.51E-04 32.03 Day 20 
681.4864  1.08E-04 29.85 Day 20 
693.5584  0.001 28.63 Baseline 
792.5546 40:6-PE 1.04E-04 28.57 Day 20 
1111.639  0.014 26.27 Baseline 
1047.6988  0.025 24.82 Baseline 
651.5352  1.65E-04 24.35 Day 20 
708.558  1.17E-04 23.41 Day 20 
858.5992 42:8-PC 2.12E-04 23.3 Day 20 
976.833 60:8 TAG 3.33E-04 22.69 Day 20 
830.5689 40:8-PC 9.27E-05 22.05 Day 20 
665.5123  5.20E-05 21.44 Day 20 
660.5574 38:5 DAG 3.25E-05 21.34 Day 20 
996.8019 62:12 TAG 0.002 21.33 Day 20 
709.5324  9.12E-04 21.22 Baseline 
920.8389  2.67E-05 21.03 Day 20 
996.8029 62:12 TAG 6.92E-04 20.25 Day 20 
944.7734 58:10 TAG 1.43E-04 19.54 Day 20 
950.8181 58:7 TAG 1.50E-04 18.69 Day 20 
952.8331 58:6 TAG 1.45E-04 18.46 Day 20 
946.8548  8.77E-06 18.4 Day 20 
625.5195  1.58E-04 18.36 Day 20 
337.2745  1.05E-04 18.27 Day 20 
994.7859 62:13 TAG 4.08E-04 17.52 Day 20 
679.471  5.64E-04 17.19 Day 20 
950.8147 58:7 TAG 1.09E-04 16.75 Day 20 
994.8787 61:6 TAG 1.86E-04 16.26 Day 20 
605.5525  3.11E-04 15.87 Day 20 
897.1374  0.001 15.49 Day 20 
1015.7151  4.21E-04 14.47 Day 20 
623.5041  1.98E-04 14.16 Day 20 
808.5903 38:5-PC 2.12E-04 13.83 Day 20 
958.8787 58:3 TAG 0.003 13.66 Day 20 
972.8024 60:10 TAG 4.29E-04 13.57 Day 20 
972.8023 60:10 TAG 9.65E-04 13.22 Day 20 
658.5401  1.24E-05 13.1 Day 20 
932.8639 56:2 TAG 0.002 12.83 Day 20 
972.802 60:10 TAG 4.69E-04 12.78 Day 20 
968.7703 60:12 TAG 6.15E-04 12.76 Day 20 
926.8184 56:5 TAG 1.02E-04 12.72 Day 20 
948.803 58:8 TAG 2.47E-04 12.71 Day 20 
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M/z Identification q Value Max Fold Change Highest Mean 
930.848  5.30E-04 12.1 Day 20 
599.5041 1.38E-04 12.04 Day 20 
625.5197 7.00E-04 11.99 Day 20 
636.5572 1.19E-04 11.98 Day 20 
942.7539 5.85E-04 11.94 Day 20 
877.212 6.82E-04 11.84 Day 20 
842.7232 3.26E-04 11.63 Day 20 
599.5043 1.53E-04 11.57 Day 20 
577.5204 2.35E-04 11.56 Day 20 
957.7875 8.23E-05 11.44 Day 20 
926.8204 2.08E-04 11.42 Day 20 
906.8498 0.002 11.41 Day 20 
965.6998 3.70E-04 11.4 Day 20 
928.8323 1.04E-04 11.28 Day 20 
948.8004 2.10E-04 11.25 Day 20 
836.6212 5.94E-04 11.22 Day 20 
973.7611 7.84E-05 10.9 Day 20 
844.7397 2.67E-04 10.86 Day 20 
931.7725 8.68E-05 10.82 Day 20 
907.7687 1.83E-04 10.68 Day 20 
623.5046 1.86E-04 10.52 Day 20 
904.8365 2.77E-04 10.49 Day 20 
950.8166 1.79E-04 10.44 Day 20 
601.519 1.13E-04 10.28 Day 20 
603.5389 1.87E-04 10.11 Day 20 
947.7447 4.41E-05 10.06 Day 20 
878.8217 4.77E-04 10.04 Day 20 
949.7287 2.54E-04 9.9 Day 20 
634.5413 1.39E-04 9.76 Day 20 
570.3577 9.27E-05 9.6 Day 20 
994.7855 0.001 9.58 Day 20 
655.4704 1.38E-04 9.3 Day 20 
864.8028 0.003 9.28 Day 20 
866.7221 4.90E-04 9.23 Day 20 
992.7703 6.79E-04 9.05 Day 20 
639.4965 1.19E-04 8.95 Day 20 
725.5633 0.006 8.89 Baseline 
602.523 1.15E-04 8.89 Day 20 
575.5054 3.21E-04 8.81 Day 20 
890.8182 0.001 8.78 Day 20 
1013.6995 9.73E-04 8.68 Day 20 
575.5042 3.26E-04 8.38 Day 20 
909.7557 2.38E-04 8.34 Day 20 
577.5244 2.67E-04 8.29 Day 20 
657.4863 1.23E-04 8.27 Day 20 
709.5894 0.006 8.03 Baseline 
682.5413 1.25E-04 8.01 Day 20 
924.8056 1.25E-04 7.95 Day 20 
947.7467 1.86E-04 7.82 Day 20 
50 
 
M/z Identification q Value Max Fold Change Highest Mean 
768.5547  2.31E-04 7.76 Day 20 
931.7732 1.86E-04 7.67 Day 20 
997.7252 9.06E-04 7.45 Day 20 
844.74 3.82E-04 7.43 Day 20 
925.7625 2.10E-04 7.24 Day 20 
892.7382 4.43E-04 7.22 Day 20 
922.79 2.57E-04 7.11 Day 20 
892.7385 6.72E-04 7.02 Day 20 
641.5124 1.25E-04 6.92 Day 20 
909.789 2.52E-04 6.87 Day 20 
902.8211 1.50E-04 6.78 Day 20 
897.1844 0.001 6.48 Day 20 
850.7894 2.08E-04 6.38 Day 20 
894.7542 1.10E-04 6.31 Day 20 
860.7712 0.002 6.3 Day 20 
888.802 6.28E-04 6.28 Day 20 
929.7581 9.67E-05 6.28 Day 20 
862.7876 0.002 6.25 Day 20 
920.775 1.71E-04 6.16 Day 20 
711.5687 0.002 6.09 Baseline 
792.5546 3.40E-04 5.96 Day 20 
551.5048 4.77E-04 5.74 Day 20 
910.7844 2.43E-04 5.69 Day 20 
945.7309 6.04E-05 5.67 Day 20 
858.7545 0.005 5.65 Day 20 
921.731 5.10E-04 5.64 Day 20 
946.7896 6.38E-04 5.63 Day 20 
899.7107 5.80E-04 5.56 Day 20 
905.7575 5.98E-04 5.52 Day 20 
915.6843 5.79E-04 5.48 Day 20 
903.7418 2.25E-04 5.47 Day 20 
882.7542 0.001 5.45 Day 20 
894.757 1.38E-04 5.4 Day 20 
705.5832 5.62E-04 5.31 Baseline 
852.8038 0.002 5.28 Day 20 
871.7596 3.23E-04 5.21 Day 20 
577.5209 3.01E-04 5.14 Day 20 
970.7875 0.002 5.14 Day 20 
601.5228 2.31E-04 5.01 Day 20 
922.791 1.07E-04 4.97 Day 20 
883.7729 3.04E-04 4.93 Day 20 
846.7583 5.99E-04 4.89 Day 20 
900.8057 1.38E-04 4.85 Day 20 
876.8086 3.14E-04 4.78 Day 20 
623.504 0.004 4.75 Day 20 
920.7722 1.29E-04 4.69 Day 20 
898.792 2.92E-04 4.67 Day 20 
558.2973 0.002 4.64 Baseline 





Table 6. List of compounds significant in plasma according to s-plot between baseline and day 28. 
Compounds are ordered based on their fold change. 
M/z Identification q Value Max Fold Change Highest Mean 
619.4822  3.34E-05 859.40 Day 28 
1101.8442  0.009 142.67 Baseline 
836.9309  0.003 78.27 Day 28 
671.576 20:5 CE 0.001 49.39 Baseline 
711.5686  0.014 28.86 Baseline 
711.5687  0.005 27.82 Baseline 
808.9314  0.002 15.55 Day 28 
725.526  0.002 15.45 Baseline 
899.1526  0.003 14.17 Day 28 
709.5521  0.002 13.36 Baseline 
901.127  3.49E-04 12.81 Day 28 
727.5438  0.002 11.5 Baseline 
923.1156  4.63E-04 11.0 Day 28 
788.9603  0.008 10.27 Day 28 
899.1103  0.001 10.15 Day 28 
877.1228  4.16E-04 9.8 Day 28 
808.8948  4.81E-04 9.44 Day 28 
788.9221  0.002 8.46 Day 28 
858.5992 42:8-PC 3.43E-04 8.09 Day 28 
897.0947  0.005 7.92 Day 28 
877.212  7.32E-04 7.18 Day 28 
629.5507  1.91E-04 6.79 Day 28 
784.8897  9.25E-04 6.77 Day 28 
429.3684  0.001 6.68 Baseline 
954.8468 58:5 TAG 0.003 5.86 Day 28 
836.6212 40:5-PC 9.02E-04 5.8 Day 28 
727.5582  0.009 5.75 Baseline 
760.9244  0.006 5.68 Day 28 
958.8787 58:3 TAG 0.071 5.42 Day 28 
826.5731  0.001 5.29 Day 28 
625.5195  0.002 5.06 Day 28 
825.7727  6.64E-06 5.05 Day 28 
862.6312 40:6-PC 9.16E-05 4.98 Day 28 
950.8181 58:7 TAG 7.63E-04 4.96 Day 28 
873.0911  0.002 4.86 Day 28 
899.2003  0.004 4.86 Day 28 
928.8323 56:4 TAG 0.004 4.83 Day 28 
603.5389  6.77E-04 4.8 Day 28 
783.1465  0.008 4.73 Day 28 
932.8639 56:2 TAG 0.03 4.71 Day 28 
930.848 56:3 TAG 0.011 4.67 Day 28 
808.5903 38:5-PC 9.13E-04 4.62 Day 28 
974.8172 60:9 TAG 0.002 4.62 Day 28 
780.5542 36:5-PC 0.008 4.54 Day 28 
912.8005 55:5 TAG 0.002 4.54 Day 28 
890.8182 53:2 TAG 3.11E-04 4.45 Day 28 
926.8184 56:5 TAG 6.84E-04 4.45 Day 28 
760.8865  3.40E-04 4.42 Day 28 
952.8331 58:6 TAG 0.005 4.41 Day 28 
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M/z Identification q Value Max Fold Change Highest Mean 
808.9784  0.004 4.4 Day 28 
888.802 4.63E-04 4.34 Day 28 
914.8153 6.35E-04 4.26 Day 28 
780.5547 0.015 4.25 Day 28 
577.5204 0.005 4.23 Day 28 
577.5244 8.63E-04 4.2 Day 28 
875.1071 2.40E-04 4.14 Day 28 
623.5046 0.006 4.14 Day 28 
789.0052 0.004 4.12 Day 28 
976.833 0.007 4.11 Day 28 
909.7557 4.46E-04 4.06 Day 28 
906.8498 0.01 4.04 Day 28 
950.8147 0.002 4.04 Day 28 
782.9126 0.023 4.02 Day 28 
904.8365 0.002 4.01 Day 28 
834.9158 0.001 3.99 Day 28 
883.2503 6.84E-04 3.99 Baseline 
972.8023 0.005 3.92 Day 28 
768.5547 1.73E-04 3.88 Day 28 
897.1844 0.011 3.88 Day 28 
601.519 0.003 3.84 Day 28 
602.523 6.14E-04 3.77 Day 28 
575.5054 0.014 3.71 Day 28 
599.5041 0.006 3.7 Day 28 
948.803 0.002 3.68 Day 28 
907.7687 6.35E-04 3.68 Day 28 
782.8759 0.005 3.67 Day 28 
926.8204 0.006 3.63 Day 28 
878.8217 0.004 3.61 Day 28 
946.8789 6.75E-04 3.6 Day 28 
860.7712 5.24E-04 3.59 Day 28 
950.8166 0.003 3.58 Day 28 
570.4589 2.96E-05 3.55 Day 28 
893.7556 5.10E-04 3.54 Day 28 
948.8004 0.003 3.49 Day 28 
931.7725 5.11E-04 3.48 Day 28 
658.5107 6.56E-05 3.46 Day 28 
925.7625 0.002 3.45 Day 28 
902.8211 8.17E-04 3.35 Day 28 
770.5693 0.014 3.34 Day 28 
947.7447 2.88E-04 3.33 Day 28 
810.9118 0.005 3.33 Day 28 
944.7734 0.024 3.32 Day 28 
810.9123 0.008 3.32 Day 28 
664.6028 0.001 3.31 Day 28 
909.789 0.002 3.3 Day 28 
432.2389 1.44E-04 3.28 Day 28 
957.2692 0.001 3.25 Baseline 
1180.3278 0.002 3.23 Baseline 
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M/z Identification q Value Max Fold Change Highest Mean 
719.5746  0.006 3.21 Baseline 
730.5645 1.17E-04 3.19 Day 28 
614.4847 7.61E-05 3.18 Day 28 
886.7853 8.58E-04 3.17 Day 28 
782.6306 0.079 3.16 Day 28 
924.8056 9.58E-04 3.15 Day 28 
862.7876 4.33E-04 3.15 Day 28 
806.8796 3.29E-04 3.14 Day 28 
903.7418 0.004 3.14 Day 28 
844.7400 0.018 3.13 Day 28 
858.7545 0.003 3.1 Day 28 
577.5209 0.001 3.1 Day 28 
922.7900 0.003 3.09 Day 28 
1105.3076 0.001 3.08 Baseline 
702.5363 9.17E-05 3.08 Day 28 
601.5228 7.91E-04 3.07 Day 28 
466.4100 3.10E-05 3.06 Day 28 
1031.2884 0.001 3.06 Baseline 
947.7467 0.003 3.06 Day 28 
919.715 0.003 3.05 Day 28 
892.7385 0.041 3.04 Day 28 
570.3577 2.30E-04 3.02 Day 28 
915.6843 0.006 3.01 Day 28 
931.7732 0.004 2.99 Day 28 
1047.6988 0.096 2.98 Baseline 
735.5486 0.013 2.97 Baseline 
876.8086 6.81E-04 2.97 Day 28 
598.4892 7.04E-05 2.96 Day 28 
884.7675 7.94E-04 2.93 Day 28 
1111.639 0.02 2.92 Baseline 
554.4629 5.01E-05 2.89 Day 28 
929.7581 7.66E-04 2.86 Day 28 
910.7844 0.005 2.85 Day 28 
899.7107 0.008 2.82 Day 28 
445.3664 0.004 2.81 Baseline 
642.5127 2.08E-04 2.79 Day 28 
725.5633 0.005 2.79 Baseline 
746.562 6.55E-05 2.78 Day 28 
1091.6983 0.016 2.76 Baseline 
945.7309 4.18E-04 2.76 Day 28 
972.802 0.009 2.75 Day 28 
369.3527 0.001 2.75 Day 28 
875.1962 0.002 2.74 Day 28 
812.6182 0.001 2.7 Day 28 
889.6687 0.044 2.7 Day 28 
822.5996 0.006 2.7 Day 28 
900.8057 6.85E-04 2.69 Day 28 
599.506 0.004 2.69 Day 28 





Table 7. List of compounds significant in plasma according to s-plot between day 15 and day 20. 
Compounds are ordered based on their fold change. 
M/z Identification q Value Max Fold Change Highest Mean 
808.6499  0.003 29.63 Day 20 
1063.665  0.055 25.84 Day 15 
836.6816  0.002 23.94 Day 20 
1087.6637  0.057 20.77 Day 15 
874.5729  0.059 20.49 Day 20 
713.5138  0.057 17.87 Day 20 
1039.673  0.04 16.95 Day 15 
924.8681  0.031 13.28 Day 20 
708.558  0.018 12.33 Day 20 
858.5992 42:8-PC 0.044 11.88 Day 20 
830.5689 40:8-PC 0.024 11.10 Day 20 
709.5324  0.02 10.15 Day 15 
1020.8035 64:14 TAG 0.077 9.26 Day 20 
974.8169 60:9 TAG 0.07 8.96 Day 20 
570.3577 22:5 lyso-PC 0.042 8.12 Day 20 
679.471  0.041 7.72 Day 20 
946.8548  0.075 6.83 Day 20 
808.5903 38:5-PC 0.045 6.79 Day 20 
764.5226 38:6-PE 0.095 6.31 Day 20 
836.6212 40:5-PC 0.069 6.23 Day 20 
792.5546 40:6-PE 0.085 6.19 Day 20 
974.8172 60:9 TAG 0.096 6.03 Day 20 
994.7859 62:13 TAG 0.076 5.16 Day 20 
972.8023 60:10 TAG 0.101 4.89 Day 20 
996.8029 62:12 TAG 0.082 4.88 Day 20 
1015.7151  0.05 4.83 Day 20 
651.5352  0.097 4.71 Day 20 
954.8468 58:5 TAG 0.128 4.15 Day 20 
965.6998  0.097 4.15 Day 20 
944.7734 58:10 TAG 0.156 4.05 Day 20 
999.742  0.052 4.05 Day 20 
681.4864  0.12 4.03 Day 20 
660.5574 38:5 DAG 0.108 4.01 Day 20 
976.833 60:8 TAG 0.14 4.00 Day 20 
582.2971  0.069 3.95 Day 15 
658.5401  0.108 3.86 Day 20 
665.5123  0.116 3.83 Day 20 
996.8019 62:12 TAG 0.17 3.73 Day 20 
949.7287  0.105 3.73 Day 20 
337.2745  0.147 3.72 Day 20 
544.5997  0.042 3.69 Day 15 
807.6372  0.128 3.66 Day 20 
625.5197  0.156 3.51 Day 20 
558.2973  0.032 3.45 Day 15 
994.7855 62:13 TAG 0.142 3.42 Day 20 
992.7703 62:14 TAG 0.145 3.29 Day 20 
972.802 60:10 TAG 0.112 3.26 Day 20 
566.3235  0.056 3.19 Day 15 
1013.6995  0.145 3.11 Day 20 
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M/z Identification q Value Max Fold Change Highest Mean 
952.8331  0.176 3.08 Day 20 
968.7703 0.175 3.07 Day 20 
972.8024 0.144 3.07 Day 20 
625.5195 0.192 3.02 Day 20 
997.7252 0.153 2.98 Day 20 
942.7539 0.233 2.98 Day 20 
544.6646 0.041 2.97 Day 15 
663.4955 0.008 2.96 Day 20 
520.5968 0.027 2.95 Day 15 
950.8181 0.191 2.90 Day 20 
994.8787 0.151 2.86 Day 20 
1048.182 0.076 2.83 Day 15 
931.7725 0.089 2.80 Day 20 
926.8184 0.123 2.75 Day 20 
973.7611 0.128 2.74 Day 20 
623.5041 0.249 2.72 Day 20 
950.8147 0.184 2.70 Day 20 
958.8787 0.27 2.70 Day 20 
682.5413 0.138 2.68 Day 20 
947.7447 0.084 2.68 Day 20 
957.7875 0.14 2.68 Day 20 
907.7687 0.143 2.65 Day 20 
791.637 0.024 2.60 Day 15 
792.5546 0.132 2.60 Day 20 
948.803 0.219 2.59 Day 20 
950.8166 0.176 2.51 Day 20 
928.8323 0.21 2.47 Day 20 
948.8004 0.194 2.46 Day 20 
807.1576 0.132 2.44 Day 20 
542.3234 0.031 2.39 Day 15 
930.848 0.26 2.38 Day 20 
520.6578 0.02 2.34 Day 15 
524.6265 0.058 2.32 Day 15 
599.5041 0.265 2.31 Day 20 
838.6339 0.12 2.30 Day 20 
806.8796 0.077 2.30 Day 20 
577.5204 0.252 2.27 Day 20 
946.7896 0.211 2.20 Day 20 
970.7875 0.211 2.19 Day 20 
924.8056 0.195 2.17 Day 20 
623.504 0.266 2.17 Day 20 
538.3886 0.089 2.11 Day 15 
1041.9351 0.04 2.09 Day 15 
806.9645 0.154 2.03 Day 20 
1059.7224 0.043 2.02 Day 15 
184.0743 0.055 2.01 Day 15 
807.3759 0.108 2.01 Day 20 





Table 8. List of compounds significant in plasma according to s-plot between day 15 and day 28. 
Compounds are ordered based on their fold change. 
M/z Identification q Value Max Fold Change Highest Mean 
619.4822  0.006 55.74 Day 28 
629.5494  0.013 47.05 Day 28 
836.9309  0.111 11.82 Day 28 
837.0174  0.154 10.94 Day 28 
725.526  0.04 9.93 Day 15 
709.5521  0.045 8.42 Day 15 
812.9249  0.013 8.14 Day 28 
629.5507  0.003 7.97 Day 28 
808.9314  0.107 5.97 Day 28 
808.8948  0.035 4.99 Day 28 
788.9603  0.083 4.78 Day 28 
788.9221  0.031 4.53 Day 28 
653.5498  0.012 4.53 Day 28 
784.8897  0.032 4.44 Day 28 
832.8984  0.058 4.24 Day 28 
952.7485 59:13 TAG 0.034 4.21 Day 15 
858.5992 42:8-PC 0.074 4.12 Day 28 
727.5582  0.056 4.04 Day 15 
816.011  0.054 3.74 Day 28 
727.5606  0.058 3.71 Day 15 
743.5374  0.062 3.60 Day 15 
862.6312 40:6-PC 0.03 3.38 Day 28 
813.9951  0.017 3.36 Day 28 
826.5731  0.037 3.24 Day 28 
836.6212 40:5-PC 0.098 3.22 Day 28 
522.6069  0.009 2.91 Day 28 
1128.6792  0.006 2.89 Day 28 
760.8865  0.021 2.87 Day 28 
760.9244  0.175 2.75 Day 28 
570.3577  0.12 2.56 Day 28 
883.2503  0.009 2.55 Day 15 
800.6167 40:2-PE 0.074 2.54 Day 28 
786.9079  0.035 2.50 Day 28 
664.6028  0.167 2.50 Day 28 
789.0052  0.064 2.47 Day 28 
603.5353  0.038 2.47 Day 28 
812.6182  0.013 2.32 Day 28 
808.5903 38:5-PC 0.164 2.27 Day 28 
1043.704  0.055 2.23 Day 28 
957.2692  0.025 2.23 Day 15 
808.9784  0.206 2.22 Day 28 
834.9158  0.071 2.22 Day 28 
425.1373  0.017 2.19 Day 28 
669.5585  0.072 2.18 Day 28 
785.5886  0.089 2.14 Day 28 
1048.0846  0.16 2.12 Day 28 
786.9081  0.052 2.11 Day 28 











Table 9. List of compounds significant in plasma according to s-plot between day 20 and day 28. 
Compounds are ordered based on their fold change. 
M/z Identification q Value Max Fold Change Highest Mean 
619.4822  0.003 63.96 Day 28 
713.5138  0.008 37.77 Day 20 
679.471  0.017 29.04 Day 20 
808.6499  1.67E-04 22.30 Day 20 
924.8681  0.004 17.19 Day 20 
708.558  0.003 16.68 Day 20 
836.6816  0.001 13.73 Day 20 
1020.8035 64:14 TAG 0.006 13.38 Day 20 
788.9603  0.002 13.03 Day 28 
658.5401  0.013 10.20 Day 20 
337.2745  0.016 9.92 Day 20 
974.8169 60:9 TAG 0.006 9.65 Day 20 
946.8548  0.002 9.61 Day 20 
1000.8324 62:10 TAG 0.011 9.14 Day 20 
660.5574 38:5 DAG 0.01 9.02 Day 20 
920.8389  0.012 8.92 Day 20 
681.4864  0.012 8.49 Day 20 
665.5123  0.011 8.39 Day 20 
807.6372  0.01 8.33 Day 20 
922.8519  0.013 8.26 Day 20 
792.5546 40:6-PE 0.006 8.23 Day 20 
944.8395  0.004 8.05 Day 20 
788.9221  0.001 7.93 Day 28 
996.8029 62:12 TAG 0.005 7.73 Day 20 
974.8172 60:9 TAG 0.006 7.02 Day 20 
682.5413  0.011 6.90 Day 20 
764.5226 38:6-PE 0.004 6.77 Day 20 
994.7859 62:13 TAG 0.003 6.72 Day 20 
992.7703 62:14 TAG 0.007 6.36 Day 20 
944.7734 58:10 TAG 0.015 5.89 Day 20 
651.5352  0.009 5.80 Day 20 
996.8019 62:12 TAG 0.018 5.76 Day 20 
972.8024 60:10 TAG 0.006 5.59 Day 20 
976.833 60:8 TAG 0.011 5.53 Day 20 
997.7252  0.007 5.52 Day 20 
954.8468 58:5 TAG 0.01 5.47 Day 20 
1013.6995  0.008 5.43 Day 20 
968.7703 60:12 TAG 0.011 5.35 Day 20 
520.5968  0.005 5.20 Day 28 
824.6169 42:4-PE 0.015 5.17 Day 28 
1015.7151  0.003 5.06 Day 20 
830.5689 40:8-PC 0.002 5.05 Day 20 
965.6998  0.012 5.02 Day 20 
826.5731  0.002 4.78 Day 28 
999.742  0.003 4.78 Day 20 
994.7855 62:13 TAG 0.012 4.73 Day 20 
972.802 60:10 TAG 0.004 4.64 Day 20 
603.5353  0.009 4.58 Day 28 
949.7287  0.012 4.57 Day 20 
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M/z Identification q Value Max Fold Change Highest Mean 
812.6182  7.44E-05 4.53 Day 28 
623.5041 0.014 4.39 Day 20 
952.8331 0.012 4.19 Day 20 
942.7539 0.043 4.17 Day 20 
950.8147 0.007 4.15 Day 20 
599.5043 0.019 4.02 Day 20 
824.617 0.011 3.97 Day 28 
625.5197 0.004 3.96 Day 20 
634.5413 0.046 3.88 Day 20 
950.8181 0.007 3.77 Day 20 
639.4965 0.044 3.73 Day 20 
837.6829 0.011 3.70 Day 28 
957.7875 0.006 3.69 Day 20 
892.7337 0.01 3.66 Day 20 
625.5195 0.011 3.63 Day 20 
800.6167 0.014 3.63 Day 28 
973.7611 0.006 3.60 Day 20 
994.8787 0.006 3.54 Day 20 
663.4955 0.004 3.54 Day 20 
948.803 0.008 3.46 Day 20 
655.4704 0.046 3.45 Day 20 
636.5572 0.036 3.44 Day 20 
972.8023 0.02 3.37 Day 20 
835.6673 0.009 3.33 Day 28 
605.5525 0.027 3.32 Day 20 
599.5041 0.019 3.25 Day 20 
948.8004 0.012 3.23 Day 20 
570.3577 4.68E-04 3.18 Day 20 
926.8204 0.016 3.15 Day 20 
844.7397 0.046 3.12 Day 20 
931.7725 0.005 3.11 Day 20 
842.7232 0.073 3.10 Day 20 
947.7447 0.004 3.02 Day 20 
641.5124 0.029 3.00 Day 20 
810.9123 0.002 3.00 Day 28 
808.5903 0.004 2.99 Day 20 
549.4886 0.013 2.95 Day 20 
623.504 0.006 2.93 Day 20 
950.8166 0.013 2.92 Day 20 
907.7687 0.008 2.91 Day 20 
792.5546 0.008 2.90 Day 20 
184.0742 0.003 2.89 Day 20 
858.5992 0.002 2.88 Day 20 
657.4863 0.039 2.87 Day 20 
926.8184 0.008 2.86 Day 20 
878.8217 0.037 2.78 Day 20 
538.3886 0.011 2.78 Day 28 
850.7894 0.019 2.78 Day 20 
892.7382 0.066 2.78 Day 20 
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920.7750  0.03 2.76 Day 20 
577.5204 0.027 2.73 Day 20 
800.6169 0.015 2.69 Day 28 
601.5190 0.019 2.68 Day 20 
866.7221 0.078 2.68 Day 20 
551.5048 0.016 2.67 Day 20 
542.3234 0.009 2.62 Day 28 
904.8365 0.027 2.62 Day 20 
599.5038 0.044 2.61 Day 20 
930.8480 0.068 2.59 Day 20 
575.5042 0.078 2.59 Day 20 
842.7216 0.054 2.57 Day 20 
953.7582 0.009 2.57 Day 20 
931.7732 0.011 2.56 Day 20 
573.4888 0.03 2.56 Day 20 
947.7467 0.011 2.56 Day 20 
970.7875 0.019 2.55 Day 20 
905.7575 0.042 2.55 Day 20 
623.5046 0.034 2.54 Day 20 
921.7310 0.042 2.53 Day 20 
820.7405 0.033 2.53 Day 20 
924.8056 0.008 2.52 Day 20 
968.7711 0.012 2.49 Day 20 
946.7896 0.005 2.45 Day 20 
808.5858 0.036 2.45 Day 20 
894.7542 0.026 2.44 Day 20 
1050.7494 0.006 2.43 Day 28 
810.9118 0.014 2.39 Day 28 
575.5054 0.056 2.37 Day 20 
807.1576 0.004 2.37 Day 20 
844.74 0.067 2.37 Day 20 
848.7727 0.014 2.37 Day 20 
602.5230 0.01 2.36 Day 20 
871.7596 0.049 2.35 Day 20 
928.8323 0.045 2.33 Day 20 
846.7583 0.026 2.33 Day 20 
892.7385 0.088 2.31 Day 20 
922.7900 0.022 2.30 Day 20 
807.3759 0.002 2.23 Day 20 
787.6727 0.011 2.20 Day 28 
929.7581 0.006 2.20 Day 20 
824.7709 0.022 2.19 Day 20 
806.9645 0.008 2.18 Day 20 
920.7722 0.024 2.18 Day 20 
801.688 0.007 2.15 Day 28 
799.6699 0.017 2.15 Day 28 
711.5490 0.020 2.13 Day 28 
894.7570 0.053 2.11 Day 20 
966.7531 0.025 2.11 Day 20 
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Table 10. List of compounds significant in liver according to s-plot between baseline and day 15. 
Compounds are ordered based on their fold change. 
 
M/z Identification q Value Max Fold Change Highest Mean 
875.6118  0.106 7.94 Baseline 
873.1752  0.091 7.26 Baseline 
873.0917  0.102 6.70 Baseline 
873.5927  0.098 6.33 Baseline 
946.8784 57:2 TAG 0.057 3.94 Baseline 
575.504  0.048 3.91 Baseline 
869.6991  0.021 3.65 Baseline 
940.8283 57:5 TAG 0.043 3.54 Baseline 
601.5195  0.061 3.39 Baseline 
960.8939 58:2 TAG 0.05 3.34 Baseline 
577.5169  0.03 3.26 Baseline 
944.8623 57:3 TAG 0.031 3.17 Baseline 
575.5033  0.047 3.16 Baseline 
844.7378 50:4 TAG 0.044 3.15 Baseline 
549.4899  0.029 3.04 Baseline 
865.6673  0.025 3.03 Baseline 
874.7883 52:3 TAG 0.049 2.98 Baseline 
922.7831 56:7 TAG 0.071 2.92 Baseline 
862.7841 51:2 TAG 0.033 2.83 Baseline 
867.6837  0.017 2.82 Baseline 
920.7671 56:8 TAG 0.061 2.82 Baseline 
890.8163 53:2 TAG 0.068 2.80 Baseline 
872.7704 52:4 TAG 0.049 2.80 Baseline 
820.7384 48:2 TAG 0.049 2.74 Baseline 
958.8785 58:3 TAG 0.026 2.72 Baseline 
916.8225  0.013 2.69 Baseline 
888.7994 53:3 TAG 0.027 2.66 Baseline 
956.8615  0.036 2.65 Baseline 
1004.854  0.027 2.64 Baseline 
883.7155  0.034 2.63 Baseline 
930.8415  0.018 2.63 Baseline 
881.7568  0.032 2.63 Baseline 
954.8264  0.022 2.60 Baseline 
990.8433  0.031 2.59 Baseline 
914.8108  0.023 2.57 Baseline 
1138.791  0.028 2.55 Baseline 
932.8539  0.035 2.53 Baseline 
889.6697  0.029 2.50 Baseline 
822.7541 48:1 TAG 0.038 2.49 Baseline 
886.7779  0.025 2.47 Baseline 
884.7646  0.027 2.47 Baseline 
818.7203 48:3 TAG 0.034 2.46 Baseline 
842.7197 50:5 TAG 0.035 2.45 Baseline 
631.4698  0.004 2.44 Baseline 
920.8593  0.037 2.40 Baseline 
925.7265 58:11 TAG 0.033 2.40 Baseline 
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M/z Identification q Value Max Fold Change Highest Mean 
930.8387  0.021 2.38 Baseline 
992.8582  0.025 2.38 Baseline 
927.745 58:10 TAG 0.022 2.37 Baseline 
897.731  0.029 2.36 Baseline 
868.7334  0.05 2.36 Baseline 
954.8413  0.027 2.32 Baseline 
918.8421  0.028 2.32 Baseline 
918.8418  0.024 2.29 Baseline 
934.8718  0.025 2.26 Baseline 
932.8579  0.023 2.25 Baseline 
915.6846  0.081 2.25 Baseline 
893.6996  0.035 2.24 Baseline 
895.7155  0.022 2.24 Baseline 
966.8446 59:6 TAG 0.103 2.23 Baseline 
855.7406  0.023 2.21 Baseline 
848.7708 58:2 TAG 0.048 2.21 Baseline 
909.7336  0.022 2.19 Baseline 
941.6994  0.024 2.16 Baseline 
948.8000 58:8 TAG 0.069 2.16 Baseline 
915.6856  0.074 2.16 Baseline 
900.8023  0.116 2.15 Baseline 
883.7714  0.081 2.12 Baseline 
930.8464 56:3 TAG 0.073 2.12 Baseline 
1006.851  0.014 2.10 Baseline 
909.7878  0.095 2.08 Baseline 
925.7613  0.101 2.08 Baseline 
980.8260  0.051 2.08 Baseline 
848.7699 50:2 TAG 0.071 2.06 Baseline 
952.7673  0.027 2.05 Baseline 
972.8932 59:3 TAG 0.067 2.05 Baseline 
898.7839 54:5 TAG 0.099 2.04 Baseline 
968.8606 59:5 TAG 0.093 2.04 Baseline 
982.8757 60:5 TAG 0.089 2.02 Baseline 
886.7923  0.037 2.02 Baseline 















Table 11. List of compounds significant in liver according to s-plot between baseline and day 20. 
Compounds are ordered based on their fold change. 
M/z Identification q Value Max Fold Change Highest Mean 
810.9098  0.007         Infinity Baseline 
810.9926 18:0/18:1-PC 0.054 354882.18 Baseline 
811.3915  0.021 5783.56 Baseline 
836.6155 40:5-PC 5.38E-04 6.63 Day 20 
575.5033  0.002 4.49 Baseline 
575.5040  0.031 3.86 Baseline 
716.5240  0.004 3.80 Baseline 
601.5195  0.031 3.74 Baseline 
848.5585  0.005 3.60 Baseline 
794.5681 40:5-PE 0.001 3.58 Day 20 
872.7704 52:4 TAG 0.003 3.55 Baseline 
744.5534 36:2-PE 0.002 3.34 Baseline 
920.7671 56:8 TAG 0.01 3.34 Baseline 
844.7378 50:4 TAG 0.017 3.20 Baseline 
577.5169  0.013 3.18 Baseline 
944.8623 57:3 TAG 0.012 3.13 Baseline 
874.7883 52:3 TAG 0.017 3.12 Baseline 
796.5297  0.002 3.04 Baseline 
889.6697  0.001 3.03 Baseline 
806.5695 38:6-PC 
(16:0/DHA) 
0.013 3.01 Day 20 
868.7334  9.64E-04 2.93 Baseline 
915.6856  0.004 2.93 Baseline 
832.5818  0.004 2.90 Baseline 
956.8615  0.003 2.83 Baseline 
894.7195  0.003 2.79 Baseline 
922.7831 56:7 TAG 0.042 2.76 Baseline 
944.764  0.027 2.57 Day 20 
915.6846  0.01 2.54 Baseline 
627.5344  0.001 2.51 Baseline 
965.7006  0.016 2.49 Day 20 
939.6851  0.005 2.49 Baseline 
980.826  0.006 2.46 Baseline 
524.372 18:0 Lyso-PC 0.004 2.46 Baseline 
925.7265 58:11 TAG 0.006 2.42 Baseline 
958.8785 58:3 TAG 0.015 2.42 Baseline 
828.5519  0.051 2.26 Day 20 
898.7839 54:5 TAG 0.028 2.22 Baseline 
768.5546 38:4-PE 0.004 2.21 Baseline 
810.6013 38:4-PC 0.008 2.20 Baseline 
888.7994 53:3 TAG 0.042 2.18 Baseline 
909.7336  0.005 2.12 Baseline 
968.8606 59:5 TAG 0.052 2.09 Baseline 
844.5263  0.091 2.09 Day 20 
918.7509 56:9 TAG 0.003 2.08 Baseline 








Table 12. List of compounds significant in liver according to s-plot between baseline and day 28. 
Compounds are ordered based on their fold change. 
M/z Identification q Value Max Fold Change Highest Mean 
873.5927  4.19E-06         Infinity Baseline 
875.6118  6.12E-06         Infinity Baseline 
873.0917  7.67E-06         Infinity Baseline 
873.1752  1.30E-05         Infinity Baseline 
810.9098  0.004         Infinity Baseline 
810.9926  0.035         Infinity Baseline 
811.3915  0.006 25901.11 Baseline 
875.1925  0.002 1872.77 Baseline 
1032.8848  2.85E-04 10.88 Baseline 
988.8325 61:9 TAG 3.57E-04 9.26 Baseline 
1030.8741  4.47E-04 9.03 Baseline 
940.8283 57:5 TAG 6.33E-05 8.30 Baseline 
996.8865  4.71E-04 7.11 Baseline 
920.7671 56:8 TAG 9.41E-04 7.10 Baseline 
990.8433  3.67E-04 6.74 Baseline 
966.8446 59:6 TAG 3.57E-04 5.93 Baseline 
575.504  0.005 5.92 Baseline 
796.5297  1.17E-04 5.83 Baseline 
575.5033  5.37E-04 5.79 Baseline 
844.7378 50:4 TAG 8.44E-04 5.57 Baseline 
973.7243  2.90E-04 5.42 Baseline 
601.5195  0.005 5.39 Baseline 
922.7831 56:7 TAG 0.005 5.38 Baseline 
952.7673  2.50E-04 4.89 Baseline 
992.8582  0.001 4.83 Baseline 
925.7265 58:11 TAG 3.52E-04 4.74 Baseline 
872.556  0.007 4.72 Baseline 
954.8264  6.11E-05 4.71 Baseline 
850.7865 50:1 TAG 0.025 4.67 Baseline 
968.768 60:12 TAG 7.11E-04 4.59 Baseline 
844.5263  0.016 4.35 Baseline 
989.7009  8.78E-04 4.21 Baseline 
549.4899  0.002 4.18 Baseline 
842.7197 50:5 TAG 6.24E-04 4.15 Baseline 
980.826  2.53E-04 4.08 Baseline 
772.5829 35:2-PC 5.38E-04 4.04 Baseline 
946.8784 57:2 TAG 0.032 4.02 Baseline 
1004.8543  7.30E-04 4.00 Baseline 
744.5511 36:2 0.003 3.99 Baseline 
968.7506  9.12E-04 3.97 Baseline 
948.8000 58:8 TAG 0.002 3.95 Baseline 
982.8757 60:6 TAG 7.15E-04 3.86 Baseline 
989.7029  0.001 3.84 Baseline 
902.8173 54:3 TAG 0.034 3.83 Baseline 
968.8606 59:5 TAG 8.07E-04 3.82 Baseline 
941.6994  4.88E-04 3.81 Baseline 
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0.004 3.78 Baseline 
886.7779 6.13E-04 3.77 Baseline 
986.909 0.002 3.70 Baseline 
1008.8923 5.03E-04 3.66 Baseline 
898.7839 7.30E-04 3.58 Baseline 
872.7704 9.15E-04 3.56 Baseline 
946.78 3.15E-04 3.55 Baseline 
889.6697 9.44E-04 3.49 Baseline 
900.8023 0.008 3.46 Baseline 
820.5252 0.003 3.43 Baseline 
884.7646 3.91E-04 3.43 Baseline 
944.8623 0.005 3.43 Baseline 
894.7195 4.23E-04 3.41 Baseline 
978.8369 1.03E-04 3.41 Baseline 
926.8121 0.004 3.37 Baseline 
956.8615 6.85E-04 3.36 Baseline 
939.6851 3.94E-04 3.34 Baseline 
920.7682 6.05E-04 3.31 Baseline 
874.7883 0.008 3.30 Baseline 
948.7965 3.18E-04 3.27 Baseline 
631.4698 2.39E-04 3.27 Baseline 
966.8445 3.25E-04 3.27 Baseline 
965.6974 3.43E-04 3.26 Baseline 
926.8159 0.002 3.25 Baseline 
930.8415 0.001 3.25 Baseline 
948.793 5.82E-04 3.21 Baseline 
915.6846 0.001 3.19 Baseline 
927.745 0.001 3.19 Baseline 
865.6673 0.002 3.17 Baseline 
984.8925 0.002 3.15 Baseline 
1138.7913 0.005 3.15 Baseline 
909.7336 4.18E-04 3.14 Baseline 
927.8165 3.18E-04 3.14 Baseline 
974.9088 0.009 3.13 Baseline 
930.8464 0.005 3.10 Baseline 
980.8595 2.66E-04 3.10 Baseline 
924.8003 0.001 3.08 Baseline 
868.7334 6.48E-04 3.07 Baseline 
836.6155 0.003 3.06 Day 28 
828.5519 0.017 3.06 Baseline 
731.6041 9.23E-04 3.06 Baseline 
994.8754 6.24E-04 3.04 Baseline 
820.7384 0.006 3.02 Baseline 
888.7994 0.004 3.00 Baseline 
939.6855 9.41E-04 2.98 Baseline 
972.8932 0.004 2.96 Baseline 
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M/z Identification q Value Max Fold Change Highest Mean 
932.8579  7.82E-04 2.93 Baseline 
1006.8507 9.00E-04 2.92 Baseline 
972.7992 9.39E-04 2.91 Baseline 
960.8939 0.041 2.91 Baseline 
950.8124 0.002 2.88 Baseline 
970.8769 0.002 2.87 Baseline 
922.7855 9.17E-04 2.87 Baseline 
934.8718 0.002 2.86 Baseline 
1006.8757 3.36E-04 2.85 Baseline 
992.861 3.37E-04 2.84 Baseline 
862.7841 0.014 2.83 Baseline 
890.8163 0.042 2.82 Baseline 
968.8603 0.002 2.77 Baseline 
932.8539 0.008 2.76 Baseline 
954.8413 2.66E-04 2.75 Baseline 
970.7819 0.002 2.75 Baseline 
941.6997 7.27E-04 2.72 Baseline 
918.7509 1.40E-04 2.70 Baseline 
982.876 0.001 2.70 Baseline 
920.8593 0.007 2.69 Baseline 
724.5246 3.15E-04 2.63 Baseline 
964.8229 4.52E-04 2.61 Baseline 
918.8421 9.06E-04 2.61 Baseline 
972.7967 0.001 2.60 Baseline 
958.8785 0.006 2.59 Baseline 
917.6987 0.005 2.59 Baseline 
551.382 4.19E-04 2.58 Baseline 
949.7266 2.91E-04 2.57 Baseline 
822.7541 0.012 2.56 Baseline 
914.8108 5.54E-04 2.52 Baseline 
915.6856 0.002 2.50 Baseline 
925.7613 0.027 2.47 Baseline 
848.5585 0.015 2.46 Baseline 
929.7572 7.27E-04 2.45 Baseline 
951.7408 3.04E-04 2.45 Baseline 
901.6134 0.002 2.45 Baseline 
867.6837 0.012 2.42 Baseline 
848.7708 0.004 2.42 Baseline 
963.6878 3.91E-04 2.42 Baseline 
909.7878 0.028 2.42 Baseline 
930.8387 0.003 2.39 Baseline 
939.8111 0.002 2.39 Baseline 
927.7407 8.60E-04 2.36 Baseline 
991.7171 0.002 2.36 Baseline 
947.7456 9.06E-04 2.31 Baseline 
830.5699 4.99E-04 2.28 Baseline 
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M/z Identification q Value Max Fold Change Highest Mean 
886.7923  8.10E-04 2.27 Baseline 
916.8225 0.003 2.27 Baseline 
943.7148 0.013 2.25 Baseline 
883.7714 0.036 2.25 Baseline 
855.7406 0.004 2.24 Baseline 
798.544 0.022 2.23 Baseline 
734.5682 0.002 2.21 Baseline 
953.7617 5.40E-04 2.20 Baseline 
856.5819 0.019 2.19 Baseline 
1020.7774 0.023 2.15 Baseline 
947.7444 0.001 2.13 Baseline 
907.7636 0.003 2.08 Baseline 
881.7568 0.047 2.07 Baseline 
907.7737 0.003 2.05 Baseline 
973.761 7.15E-04 2.05 Baseline 
918.8418 0.02 2.03 Baseline 
832.5818 0.013 2.01 Baseline 






Table 13. List of compounds significant in liver according to s-plot between day 15 and day 20. 
Compounds are ordered based on their fold change. 
 
M/z Identification q Value Max Fold Change Highest Mean 
836.6155  0.002 6.29 Day 20 
794.5681 40:5-PE 0.002 4.45 Day 20 
848.5585  0.015 3.01 Day 15 
832.5818  0.016 2.48 Day 15 
806.5695 48:6 (16:0/DHA) 0.005 2.46 Day 20 
744.5534 36:2-PE 0.078 2.26 Day 15 
766.553  0.01 2.18 Day 20 
828.5519  0.036 2.14 Day 20 
810.6013 38:4-PC 0.028 2.13 Day 15 
808.5837 48:5-PC 0.015 2.09 Day 20 
844.5263  0.059 2.05 Day 20 
967.7147  0.064 1.98 Day 20 
429.2408  0.078 1.83 Day 20 
768.5546 38:4-PE 0.068 1.83 Day 15 
391.2846  0.076 1.82 Day 20 
391.2847  0.082 1.81 Day 20 
803.5438  0.084 1.78 Day 20 
803.544  0.09 1.78 Day 20 
945.7298  0.061 1.69 Day 20 
848.7699 50:2 TAG 0.047 1.64 Day 20 
796.5796  0.041 1.62 Day 15 
819.5169 40:8-PG 0.136 1.58 Day 20 
531.4086  0.052 1.57 Day 20 
919.7153  0.193 1.52 Day 20 
536.6132  0.167 1.50 Day 20 
569.4332  0.187 1.50 Day 20 
943.7146  0.164 1.48 Day 20 
834.7539  0.165 1.44 Day 20 
786.5998 36:2-PC 0.189 1.43 Day 15 
788.6183 36:1-PC 0.144 1.31 Day 15 






Table 14. List of compounds significant in liver according to s-plot between day 15 and day 28. 
Compounds are ordered based on their fold change. 
 
M/z Identifications q Value Max Fold Change Highest Mean 
844.5263  0.004 9.09 Day 20 
828.5519  0.002 6.93 Day 20 
806.5695 48:6-PC 
(16:0/DHA) 
0.003 5.37 Day 20 
965.7006  0.008 4.30 Day 20 
948.8000 58:8 TAG 0.002 3.26 Day 20 
926.8159 56:5 TAG 0.004 3.16 Day 20 
967.7147  0.005 2.90 Day 20 
946.7800  0.008 2.88 Day 20 
744.5534 36:2-PE 0.002 2.82 Day 28 
948.7930  0.001 2.75 Day 20 
969.7304  0.001 2.74 Day 20 
924.8003 56:6 TAG 0.009 2.57 Day 20 
945.7298  0.003 2.32 Day 20 
929.7572  0.004 2.28 Day 20 
965.6974  0.046 2.20 Day 20 
836.6155 40:5-PC 0.044 2.16 Day 20 
920.7671 56:8 TAG 0.011 2.13 Day 20 
922.7855 56:7 TAG 0.021 2.12 Day 20 








Table 15. List of compounds significant in liver according to s-plot between day 20 and day 28. 
Compounds are ordered based on their fold change. 
 
M/z Identifications q Value Max Fold Change Highest Mean 
844.5263  0.004 9.09 Day 20 
828.5519  0.002 6.93 Day 20 
806.5695 48:6-PC 
(16:0/DHA) 
0.003 5.37 Day 20 
965.7006  0.008 4.30 Day 20 
948.8000 58:8 TAG 0.002 3.26 Day 20 
926.8159 56:5 TAG 0.004 3.16 Day 20 
967.7147  0.005 2.90 Day 20 
946.7800  0.008 2.88 Day 20 
744.5534 36:2-PE 0.002 2.82 Day 28 
948.7930  0.001 2.75 Day 20 
969.7304  0.001 2.74 Day 20 
924.8003 56:6 TAG 0.009 2.57 Day 20 
945.7298  0.003 2.32 Day 20 
929.7572  0.004 2.28 Day 20 
965.6974  0.046 2.20 Day 20 
836.6155 40:5-PC 0.044 2.16 Day 20 
920.7671 56:8 TAG 0.011 2.13 Day 20 
922.7855 56:7 TAG 0.021 2.12 Day 20 







The analysis of this data was performed on two levels.  The first approach was a targeted 
approach to identify lipid acyl species that were already examined using a triple quadrupole mass 
spectrometer at 15 days and 20 days of pregnancy [19].  The second approach was a non-targeted, 
discovery assessment of the rat lipidome throughout pregnancy. This was an attempt to identify 
all lipid compounds, but this was truncated at the level of compounds that made up the 85% of the 
total ion intensity signal (85% most abundant compounds) due to the large number of compounds 
detected.  Principal component analysis combined with as several s-plots were used on the dataset 
to indicate compounds that changed during pregnancy list in baseline as well to examine 
differences between each time point.  There was also an attempt to match the measured mass-to-
charge of compounds to specific lipid identities.  All of the mass spectrometry approaches in this 
thesis relied on data generated using a QTOF mass spectrometer  
For the targeted approach, acyl species of PC in plasma and liver and of PE in liver were 
examined across all four time points (Figures 11 and 12). and compared to previous results 
examining day 15 and 20 of pregnancy. The present analysis confirmed the main previous finding 
that 16:0/DHA PC increases dramatically while the increase in 18:0/DHA PC is significant but 
more modest in plasma between 15 and 20 days of pregnancy.  This also confirmed the main 
observations in liver between 15 and 20 days of pregnancy with 16:0/DHA PC increasing but not 
16:0/DHA PE, while 38:4 PC and PE decreased. This analysis also shows a modest increase in 
plasma 16:0/DHA-PC at day 15 compared with baseline but not the liver. More interestingly, there 
was a clear decrease in 16:0/DHA-PC in the liver in the postpartum period compared with day 20 
of pregnancy, to well below baseline levels. Plasma 16:0/DHA-PC did decrease as well following 
the same trend as the liver however postpartum levels matched that of baseline levels. A Similar 
trend was also seen with 18:0/DHA-PC which decreased in the postpartum period compared with 
day 20 in both plasma and liver however plasma postpartum levels remained elevated compared 
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with baseline. This continued increase of DHA levels in plasma postpartum coupled with 
decreased hepatic DHA mobilization may indicate other tissues are responsible for postpartum 
DHA mobilization. Further investigation into postpartum periods is required as mammary tissue 
could be responsible for this continued DHA demand for offspring transport through breastmilk 
[68]. 
Another interesting observation was the decreased levels of liver arachidonate (ARA, 
20:4n-6) in 38:4-PC at day 20 of pregnancy compared with baseline. This decrease would result 
in similar levels of ARA and DHA due to the high abundance of ARA in baseline. This high 
abundance could be a factor in why ARA does not increase during pregnancy despite its 
importance for fetal development [69]. It is also likely that carbon chain length selectivity might 
be a factor in determining ARA levels as 20 and 22 carbon PUFA follow different change patterns 
during pregnancy [70].  
Using the same dataset, we set out to establish a baseline level of the top 85% most 
abundant compounds in both plasma and liver. Baseline samples were used to limit the number of 
compounds as pregnancy would cause an increase in various lipids that might not be present during 
baseline. This was also used as a reference for any changes that would occur during pregnancy and 
their impact relative to the presence of other more abundant compounds. This approach for top 
85% of the UHPLC signal is not novel as a similar approach has been previously conducted by 
others [71, 72]. Plasma baseline levels for top 85% provided over 802 compounds compared to 
158 for the liver. Therefore, I only attempted to identify the compounds with the top 50% 
abundancy for plasma of which about 1/3 was successfully identified. The most abundant 
compounds in the liver were identified at a similar identification success rate of 36% but more 
surprisingly, 10 individual lipids made up over 40% of the total abundance with 18:0/20:4-PC 
alone contributing almost 12% of the total abundance of lipids in liver. Overall, the liver contained 
predominantly PC and TAG species, with a few PE and very limited quantities of other lipid pools. 
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In contrast, the plasma contained similar ion abundances of PC, TAG, lyso-PC, and PE species as 
well as smaller pool of other lipids.  
The principal component analysis graphs (Figure 13) clearly showed differences between 
the different time points in both liver and plasma. Two plasma samples were removed (from day 
15 and day 20) due to issues with Progenesis failing to extract peaks successfully with the settings 
established. Significant compounds identified from s-plots for both plasma and liver show 
increases predominantly in the TAG and PC pools, which is consistent with previously available 
data. Most changes were observed between baseline and day 20 (baseline vs. end of pregnancy) as 
well as day 20 vs. day 28 (end of pregnancy vs. postpartum). In plasma, the highest increase 
observed was in two isomers of 60:9 TAG, 38:6-PE and 40:6-PE at the end of pregnancy compared 
with baseline. Although we were unable to verify the acyl chains of these compounds, it is likely 
that the PE compounds are 16:0/DHA-PE and 18:0/DHA-PE. A number of TAG species decreased 
at day 28 compared with day 20, most notably 64:14 TAG and 60:9 TAG that was mentioned 
earlier.  
In the liver, the lipidome changes exhibited a much different pattern as many compounds 
decreased at day 20 compared with baseline with a few exceptions being 40:5-PC, 40:6-PC, and 
most importantly 38:6-PC (16:0/DHA-PC). The postpartum time point also showed decreases in a 
number of compounds such as 16:0/DHA-PC, 58:8 TAG and 56:5 TAG, and with only 36:2-PE 
increasing at this time point. Interestingly liver 16:0/DHA-PE and 18:0/DHA-PE were relatively 
stable during pregnancy with evidence of a decrease only at postpartum.  It appears that in the liver 
during pregnancy, there are mechanisms involved in maintaining hepatic DHA status while 
producing 16:0/DHA PC for export as a component of lipoproteins.  After pregnancy, it appears 
that mechanisms maintaining hepatic DHA status stop, despite what we hypothesize is a continued 
demand for DHA to support maternal lactation.   
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Overall, despite our initial objective to characterize the lipidome throughout pregnancy, 
we were unable to identify compounds past the “Brutto” level. This was due in part to the nature 
of MSE data collection.  In MSE, the matching of MS data with MS/MS data is not precise, but 
relies on retention time-matching between parent ions from the low-energy scans (MS data) and 
daughter ins from high-energy collision-induced dissociation scans (MS/MS data). When many 
compounds are detected at similar retention times, the ability to match MS/MS data (fragmentation 
spectra) to MS data (parent ions) become  severely compromised. Therefore, specific acyl chains 
composition (“medio” species) and the -sn position of the acyl chains (“genio” species) cannot be 
identified. Strategies to improve our MSE approach are discussed in the next chapter as part of the 








 In this section, I will address the proposed hypotheses, and examine the limitations of the 
research completed and propose possible solutions to be considered for future research.  I will also 
attempt to integrate the gene expression results and the lipidomic findings with the existing 
literature.  
Hypothesis 1. There will be an increased expression of LPCAT1 in maternal hepatic tissue 
relative to baseline to accommodate the incorporation of DHA into lyso-PC. 
Hypothesis 2. There will be an increased expression of Acsl 3, to accommodate the increased 
DHA remodeling through acyltransferases. 
Hypothesis 3. There will be a decrease in the expression of PLA2G15 in maternal hepatic tissue 
relative to baseline to reduce the remodeling of PC newly synthesized by PEMT. 
 I hypothesized that I would observes various changes during pregnancy that would result 
in increased availability of DHA for fetal transport.  This included hypotheses that an 
acyltransferase and an acyl-CoA synthase would be increased to biosynthesis more lipids that 
contain DHA.  I also hypothesized that a phospholipase involved in acyl chain remodeling of lipids 
would be decreased while lipoprotein assembly enzymes would be increased.  Finally, I 
hypothesized that 16:0/DHA-PC in plasma and liver would be lower at baseline and postpartum 
as compared with time points during pregnancy. Contrary to my initial hypothesis, there was no 
increased expression of any acyltransferase that could point to increased remodeling and 
incorporation of DHA to PC. AGPAT2 mRNA decreased at day 20 compared to baseline (p>0.05), 
pointing to decreased lyso-phosphatidic acid to phosphatidic acid conversion. This results in 
decreased levels of a number of lipids in the liver such as 18:0/18:1-PC, 52:4 TAG, 36:2-PE, 56:8 
TAG, 50:4 TAG as well as other lipids that decreased at day 20 compared to baseline which can 
be found in Table 11. Acsl 3 decreased throughout pregnancy refuting my hypothesis, while Acsl 
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6 increased during pregnancy. As for the phospholipases, there was decreased mRNA expression 
throughout pregnancy. As hypothesized, the decreased expression was most prevalent in PLA2G15 
with its mRNA and protein decreased significantly at day 15 and 20 of pregnancy and increased 
significantly in the post-partum. I believe that this enzyme is responsible for remodeling PEMT 
synthesized 16:0/DHA-PC during non-pregnant state as observed initially by Ridgway and Vance 
[10]. This protein’s downregulation in pregnancy coupled with the decreased Acsl 3 is believed to 
result in increased DHA presence in PC which in turn will enrich lipoproteins’ membrane with 
DHA for mobilization.  
Hypothesis 4. There will be an increased expression of MTTP, ABCA1, as well as SREBP at the 
end of pregnancy compared to baseline to support increased VLDL assembly. 
Lipoprotein assembly proteins show no mRNA increase during pregnancy, opposing our initial 
hypothesis. A significant increase was observed in MTTP but only occurred in the post-partum. 
ApoA1 and A2 increased during pregnancy, however A1 decreased in the postpartum while A2 
continued to increase. Although there was no increased expression of lipoprotein assembly 
proteins, increased activity could be responsible for the hyperlipidemia occurring during 
pregnancy, as explained earlier with ABCA1. ApoA2 is hypothesized to assist the delivery of DHA 
to both the placenta as well as mammary tissue. Careful consideration is to be given as the rat 
model is considered ideal for fatty acid synthesis research in comparison to humans, but fails in 
mimicking the lipoproteins in humans. It is clear however that lipoproteins play a vital role in the 
delivery of DHA to the fetus throughout the course of pregnancy as well as postpartum and this 
data provides HDL as a target for research in more suitable models. 
Hypothesis 5. Plasma 16:0/DHA-PC at baseline and postpartum will be similar and lower than 
levels at day 20. 
Hypothesis 6. Hepatic 16:0/DHA-PC at baseline and postpartum will be similar and lower than 
levels at day 20. 
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Lipidomic analysis of plasma and liver samples was first used to detect the most abundant 
lipids in the non-pregnant rats (Table 2 and 3), which interestingly points that only 5 PC species 
and 5 TAG species are responsible for over 40% of the lipid abundances in the liver. Plasma 
samples on the other hand show that each individual lipid species have much lower contributions 
to the total abundance. The most abundant lipids in plasma were 6 PC species, contributing ~12% 
of total abundance combined. As hypothesized, plasma and liver 16:0/DHA-PC significantly 
decreased in the postpartum alongside 18:0/DHA-PC, pointing to secondary mechanism for DHA 
mobilization during this period.  
6.2 Consolidating the Results with the Literature 
PC species that contained DHA (16:0 and 18:0) both increased in plasma and liver at day 
20 of pregnancy compared to baseline, however 16:0/DHA decreased below baseline levels in the 
postpartum, confirming our hypothesis, while 18:0/DHA returned to baseline levels. This could be 
due to the high demand for mobilization of maternal DHA remaining in the postpartum to support 
lactation, but a downregulation of hepatic support as a result of changed hormone signaling 
postpartum.  It could be possible, the mobilization and synthesis of DHA for the offspring in the 
postpartum shifts from primarily being hepatic during pregnancy, to being driven by mammary 
tissue in the postpartum. Further examination of the post-partum period is clearly needed. PC 
species containing ARA exhibited a different trend in plasma during pregnancy, which should not 
be entirely surprising. Although ARA is as important for fetal development as DHA [69], the high 
abundance of ARA in the lipids of plasma and the liver before and during pregnancy indicates that 
specialized adaptations to mobilize ARA to meet fetal transport are not necessary.  In contrast, 
DHA levels in plasma can be quite variable and largely dependent on dietary intake habits.  
Therefore, there may have been evolutionary pressure to develop adaptations during pregnancy to 
ensure a supply of DHA to meet fetal demand.  There is previous evidence suggesting an 
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adaptation to shift PUFA metabolism towards high amounts of 22 carbon PUFA over 20 carbon 
PUFA during pregnancy [73].   
 These results together with our previous PEMT study [19] provides a more in-depth 
understanding of DHA mobilization during pregnancy. DHA enriched PE is converted to PC 
through PEMT in the non-pregnant state. Increased expression of PEMT in pregnancy results in 
higher prevalence of 16:0/DHA-PC, however due to the remodeling effect of PLA2G15, 
downregulation of this enzyme is crucial. By ensuring the integrity of this PC species, it allows 
the liver to incorporate it to lipoproteins membranes to be transferred through the plasma to the 
fetus. These results also regarding the post-partum period in which PEMT is downregulated to 
baseline levels and PLA2G15 is upregulated above baseline levels. As DHA continues to be 
transported to the offspring through breastmilk, possible alterations to these enzymes as well as 
mammary tissue enzymes could be responsible for meeting offspring DHA demands. This requires 
a post-partum focused study to understand DHA mobilization.  
 
6.3 Limitations 
This thesis has limitations due to study design and analytical techniques.  For study design, 
extrapolating findings from rodent pregnancy models must be done with caution as brain 
development differs in humans.  The brain growth spurt occurs during the early postpartum of the 
rat whereas this occurs during pregnancy in humans.  Specifically the first week postpartum in the 
rat pup brain development tends to match human fetus brain development in the third trimester 
[74]. However, the brain continues to develop in both rats and humans well after the brain growth 
spurt period, and in humans this can be well into adulthood [75]. At 7 days postpartum in this 
study, plasma DHA remained increased as compared with baseline suggests that there may be 
postpartum adaptations to mobilized DHA still occurring in our rat model. Examining the 
postpartum period more thoroughly in the may provide additional insights.   
78 
 
Analytically, we used a targeted gene expression approach.  Previously, we had used a 
transcriptomics approach [19], but, this was difficult to interpret due to numerous changes in 
mRNA expression during pregnancy in numerous metabolic pathways, which made it difficult to 
observe subtler changes in fatty acid and lipid metabolism.  Therefore, to examine fatty acid and 
lipid metabolism, we focused on specific gene product targets. Unfortunately, the lack of both 
mRNA primers as well as protein antibodies for several acyltransferases limited our ability to 
examine several gene product targets related to DHA mobilization during the pregnancy. Some 
primers used also did not span the coding DNA sequence for the intended gene which may explain 
why significant changes were not observed. In While activity assays have been defined for some 
of the gene products, many have not and it was difficult to perform such assessments within the 
timeline of this thesis. Future examination of these enzymes and their activity could yield more in 
depth understanding of lipid synthesis and mobilization during pregnancy. 
The novelty of MSE data approach presented several challenges. Some of these challenges 
were similar to the previously conducted transcriptomic analysis, as untargeted “-omic” 
approaches have a tendency to highlight gene products or compounds with large fold changes 
regardless of absolute abundances. For lipidomics, this can be particularly deceiving as changes in 
trace level compounds can get highlighted over large absolute changes in highly abundant 
compounds.  This is evident when examining 16:0/DHA-PE fold change increase and its 
abundance to its PC counterpart. Although the PE molecule had a much higher fold change, its 
abundance was minimal as compared with 16:0/DHA-PC.  
The major limitation with lipidomic analyses in this thesis was the difficulty in identifying 
specific acyl-species in the lipidome.  The high complexity of the samples, the large number of 
compounds present, and their incomplete chromatographic separation meant that we were unable 
to link MS and MS/MS data precisely to be able to verify compounds we had not observed 
previously, despite using software designed for MSE. This is due to MSE analysis performing 
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consecutive scanning ions in low and high energy resulting in parent ions and their fragments, 
respectively. As many compounds are detected at the same retention time due to co-elution, the 
association of specific fragments and their parent ion is lost. Consequently, we were unable to 
address an objective of characterizing the lipidome at the acyl species level throughout pregnancy, 
and were only able to list Brutto species for most of the lipidome. The Progenesis software used 
provided further obstacles.  Compounds were often misidentified compounds, or not detected due 
to the data import/filtering settings used. While trial and error adjustment of import and peak filters 
helped detect more compounds of interest, I was not able to improve the misidentification of 
compounds. This trial and error approach to tweaking the software was also limited by the large 
size of the raw MSE data files (7-10GB per sample) which took a long time to import and process. 
While the MSE approach had utility in screening samples for lipidome changes across many types 
of lipids, caution is advised when examining and interpreting the individual lipid species generated 
as it appears the identifications are often crude and lack the verification that is associated with 
precisely linked MS/MS data collection approaches such as data dependent acquisition (DDA) 
using an inclusion list for compounds of interest [76].   
The improvement of MSE although difficult, might still be possible due to the availability 
of different software employing different analysis algorithms. It is also possible that conducting 
analysis on less complicated samples might improve our analysis method and yield better strategies 
for future analysis. It may also possible to improve our resolution and separation of individual 
compounds by improved chromatography and/or by using ion mobility separation techniques. This 
would possibly lead to better ability to link MS and MS/MS data and therefore increase the 
identification rate of compounds.  
6.4 Conclusion  
 
During pregnancy, there are many interconnected mechanisms responsible for facilitating and 
supporting fatty acid mobilization. A critical finding in this thesis was that hepatic Phospholipase 
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A2 G15 was decreased at 20 days of pregnancy which is associated with the large increase in 
16:0/DHA-PC in plasma and liver.   This supports a previous hypothesis that there are metabolic 
adaptations during pregnancy to mobilize DHA into 16:0/DHA-PC in the circulation.  Specifically, 
this finding supports the observation that PC synthesis by PEMT is upregulated during pregnancy 
[9, 19].  The finding of decreased PLA2G15 during pregnancy also coordinates well with an 
observation t newly synthesized PC from PEMT is rich in DHA but that in the non-pregnant state, 
DHA is rapidly removed from the new PC through remodeling [10].  Downregulated PLA2G15 
during pregnancy would result in less remodeling of new PC synthesized from PEMT and allow 
for DHA-rich PC to persist and potentially enter the circulation as a component of lipoproteins. 
Lipidomic analysis of plasma and liver samples of pregnant rats identified TAG, PC and PE 
species that are responsible for pregnancy hyperlipidemia and transportation of fatty acids to the 
fetus and offspring. This is a novel approach due to the lack of non-targeted analysis of pregnancy 
tissues, however limitations of the MSE data compromised the ability to fulling characterize the 
lipidome throughout pregnancy.   
An adequate supply DHA to the fetus and infant during the late stages of pregnancy and 
postpartum is important for optimal brain development. Maternal DHA blood status during 
pregnancy is also an important predictor for infant health outcomes such as asthma [77].   We have 
demonstrated evidence of novel maternal adaptations during pregnancy that suggest that synthesis 
and mobilization DHA during pregnancy is complex and involves several metabolic pathways. 
Through this research, we were able to identify an enzyme, PLA2G15 that further supports a role 
for PEMT in mobilizing DHA as 16:0/DHA-PC for fetal transport.  In addition, we provide further 
mechanistic support that 16:0/DHA PC may be an important blood biomarker of maternal DHA 
status during pregnancy.  Further evaluation of this biomarker in pregnant populations, could lead 
to improved dietary recommendations for DHA intake during pregnancy, but lead to specific blood 
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level targets to identify women and their future infants that could benefit from targeted 
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